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ABSTRACT 
 
INVESTIGATION OF THE EFFECTS OF NICOTINE AND LEVAMISOLE ON 
SW620 COLON ADENOCARCINOMA CELLS USING A CUSTOMIZED R-
ROUTINE FOR AUTOMATED MICROARRAY ANALYSIS 
 
Muammer ÜÇAL 
MSc. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Dr. Özlen KONU 
August 2010 
Nicotine, the addictive component of tobacco, shows proliferative and antiapoptotic 
activity in cancer cells. Levamisole, an antihelmintic, on the other hand, has been tested 
as an additive chemotherapeutic agent and in treatment of nephrotic syndrome. Nicotine 
and levamisole are both agonists of nicotinic acetylcholine receptors; effects of these 
two agents have not been studied in colon cancer transcriptome. In this study, nicotine 
and levamisole exposed SW620 colon cancer cells, at a dose of 1 μM for 7 days, were 
studied with respect to changes in expression using microarrays. For data analysis, a 
custom R-routine which makes extensive use of open source R-BioConductor Project 
and associated packages has been written; and it is composed of three modules: 
QualCont  module performs quality controls supported with several visual 
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representations and normalization of the raw data; DEGidentifier module performs 
identification of differentially expressed genes (DEGs) supported with Heatmap and 
Venn Diagram; and finally FuncAnn module, composed of four main functions, 
performs functional annotation and analysis of the results in terms of Gene Ontology, 
pathway analysis, supported with graphics and pathway networks  
All arrays passed the quality control criteria. In this study, we show that nicotine and 
levamisole treatments affect the transcriptome similarly in SW620 cells in terms of both 
the differential expression and functional analysis. Our findings implicate nicotine and 
levamisole in steroid biosynthesis, cholesterol biosynthesis and aminoacid degradation 
metabolisms. Confirmatory analyses have been performed by real time RT-PCR for a 
selected set of genes. 
 
Keywords: nicotine, levamisole, SW620, colon cancer, custom R routine, automated 
microarray analysis 
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ÖZ 
NİKOTİN VE LEVAMİSOLÜN SW620 KOLON ADENOKARSİNOM 
HÜCRELERİ ÜZERİNDEKİ ETKİLERİNİN ARAŞTIRILMASI VE 
OTOMATİK MİKRODİZİ ANALİZİ İÇİN ÖZEL R PROGRAM RUTİNİ 
GELİŞTİRİLMESİ VE UYGULANMASI 
 
Muammer ÜÇAL 
Moleküler Biyoloji ve Genetik Yüksek Lisansı 
Tez danışmanı: Doç. Dr. Özlen KONU 
August 2010 
Sigaranın bağımlılık yapıcı madde olarak bileşeni nikotin, hücre çoğalımına neden 
olmak suretiyle kanserojen etki gösterir. Levamisol bir antihelmintik olarak 
kullanımdaysa da kolon kanserinde bağışıklığı arttırmak amaçlı kemoterapi ajanı olarak 
ve steroid hassasiyeti olan nefrotik sendromlu hastalarda denenmiş ve kullanılmıştır. Bu 
çalışmada 1uM ve 7 gün boyunca uygulanan nikotin ve levamisolün SW620 kolon 
kanseri hücre hattı üzerindeki etkilerini mikrodizi analizi ile gerçekleştirilmiştir. 
Verilerin analizi için açık kodlu R-BioConductor projesi paketlerinin yoğun olarak 
kullanıldığı özel bir R program tasarlanıp uygulanmıştır. Program rutini üç ana 
modülden oluşmaktadır: QualCont modülü, mikrodizilerin ve verilerin kalite kontrol 
analizleri için grafik destekli sonuçlar üretir ve veri normalizasyonunu gerçekleştirir; 
DEGidentifier modülü, gruplar arasındaki ifade farkı gösteren genlerin tespitini yapar ve 
bu konudaki sonuçları Venn şeması ve gen ifade haritası ile birlikte sunar ve son olarak 
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FuncAnn modülü dört ana fonksiyondan oluşmaktadır ve Gen Ontolojisi, yolak analizi 
bakımlarından verilerin işlevsel analiz ve açıklamalarını yapar, grafikler ve gen ağ 
sonuçları ile destekler. 
Bu çalışma nikotin ve levamisolün SW620 hücreleri üzerinde hem gen ifade 
farklılaşması hem de işlevsel yolaklar bakımından oldukça benzer yanıtlar 
oluşturduğunu göstermektedir. Bulgularımız, nikotin ve levamisolün steroid biyosentezi, 
kolesterol biyosentezi ve aminoasit yıkımı metabolizmalarında oldukça güçlü bir etkiye 
sahip oldukları yönünde olmuştur. Mikrodizi bulguları gerçek zamanlı RT-PCR 
analizleri ile desteklenmiştir. 
 
Anahtar sözcükler: nikotin, levamisol, SW620, kolon kanseri, özel R rutini, otomatik  
mikrodizi analizi
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1. INTRODUCTION 
 
1.1. Nicotine 
1.1.1. History of nicotine – A general overview 
 
Although tobacco is known to have been consumed for over two thousand years, 
nicotine, the addictive component of tobacco, was discovered within the last two 
centuries. Initial isolation of nicotine dates back to 1807 yet nicotine was first purified 
and identified as an alkaloid with a molecular formula of C10H14N2, by Reimann and 
Posselt in 1828 (Borio, 1995-2010). 
In the 20
th
 century nicotine and nicotine containing compounds were used in agriculture 
and stock breeding as insecticides, and research records show that the scientists were 
interested in the effects of nicotine on nervous system, muscle irritability as well as 
agricultural aspects of its usage. The first study to investigate the role of nicotine in 
smoking habit came in 1945 (Finnegan et al., 1945). The first powerful links between 
smoking and lung cancer was not provided until 1950 when three different 
epidemiologic studies, one published in Britain and two published in the United States, 
demonstrated an association (Doll and Hill, 1950; Levin et al., 1950; Wynder and 
Graham, 1950). In 1955, Essenberg et. al. published a study on experimental lung tumor 
incidence in mice exposed to tobacco smoke from cigarettes low in nicotine (Essenberg 
et al., 1955). In the second half of the century, nicotine and cancer relationship has been 
one of the most investigated aspects of nicotine effect on human health. By no means 
less important, such popularity brought the chance of broad investigation of nicotine 
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along the 20
th
 and 21
st
 centuries in all aspects of health and disease, including toxicity, 
pharmacology, neurobiology, development, and even in its therapeutic usage. 
1.1.2. Structure and Properties 
 
IUPAC (International Union of Pure and Applied Chemistry) name of the nicotine is 3-
(1-methyl-2-pyrrolidinyl)pyridine. It is bicyclic compound with a pyridine cycle and a 
pyrrolidine cycle (Figure 1) 
Elemental components of nicotine are carbon, hydrogen and nitrogen, and the molecular 
formula of nicotine is C5H4NC4H7NCH3  while the molecular weight is 162.23 grams 
per mole. 
 
Nicotine, melting at -79
o
C and boiling at 247
o
C, is found in its liquid state at room 
temperature. It is miscible in water; very soluble in ethyl alcohol, ether, and chloroform 
(PMEP, 1985). 
1.1.3. Metabolism 
 
Nicotine is a weak base with a pKa of 8.0 (Fowler, 1954) and its absorption is reduced in 
its ionized form. Therefore, absorption of nicotine is dependent on the pH of the smoke: 
the more alkaline the smoke, the more unionized and the easier absorbed the nicotine in 
Figure 1: Chemical structure of nicotine. Adapted from (Benowitz and 
Jacob, 1994) 
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mouth (Armitage et al., 1978; Brunnemann and Hoffmann, 1974; Gori et al., 1986; 
Sensabaugh and Cundiff, 1967). Being carried in basic tar droplets, a larger portion of 
the nicotine stays in unionized form which facilitates rapid pulmonary absorption 
(Hukkanen et al., 2005; Pankow, 2001; Pankow et al., 2003). After a puff, nicotine is 
rapidly absorbed in the fluid with a pH of 7.4 in the human lung and high levels of 
nicotine reaches to brain in 10 to 20 seconds (Benowitz, 1990; Hukkanen et al., 2005). 
Thus, nicotine‟s effects on the physiological state of an organism can be rapid and might 
depend on the dose and timing of the exposure.   
Nicotine acts through binding nicotinic acetylcholine receptors (nAChRs) (discussed 
below) and exerts its effects through downstream effectors. From this route nicotine is 
able to enter to cell with endocytosis of desensitized receptors (Green and Millar, 1995; 
Kittler and Moss, 2001). On the other hand, nicotine can also enter to the cell itself; 
unlike for acetylcholine (ACh), membranes are readily permeable to nicotine, as it 
permeates at least through alveoli and capillary walls (Lester et al., 2009). Therefore, it 
is plausible that nicotine passes the cellular membrane also. As a matter of fact, it was 
shown that nicotine can promote assembly of α4β2 AChRs by inducing an active or 
desensitized conformation in the ER lumen (Kuryatov et al., 2005), which indicates 
nicotine, either permeating through the membrane or being internalized by endocytosis 
process, takes intracellular roles besides acting excitatory for nAChRs. 
There are six major metabolites of nicotine. The most important of these is cotinine to 
which about 70 to 80% of the nicotine is converted (Benowitz and Jacob, 1994). In this 
transformation nicotine is first converted to nicotine iminium ion, by a cytochrome P450 
system, primary enzyme being CYP2A6 (Murphy, 1973) and second iminium ion is 
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converted to cotinine by a cytoplasmic aldehyde oxidase (AOX1) (Brandange and 
Lindblom, 1979). Cotinine is then metabolized to trans-3‟-hydroxycotinine again by 
CYP2A6 (Nakajima et al., 1996). Another primary metabolite is nicotine N –oxide and 
this conversion is catalyzed by a flavin – containing monooxygenase 3 (FMO3) 
(Cashman et al., 1992). A study in 1975 demonstrates that this metabolite is not further 
metabolized and rather is reduced back to nicotine (Dajani et al., 1975) while another 
indicates that this reduction takes place in large intestine (Beckett et al., 1970). These 
two metabolites, cotinine and nicotine  N-oxide, are formed by oxidation of the 
pyrrolidine ring. 
Two other metabolites are formed by a methylation and glucuronidation of the pyridine 
ring, respectively: nicotine isomethonium ion (N-methylnicotinium ion) (McKennis et 
al., 1963) and N-quaternary glucuronide (Benowitz and Jacob, 1994). Nicotine 
isomethonium ion formation is likely to be catalyzed by indolethylamine N-
methyltransferase (INMT) enzyme, which is also known as nicotine N-
methyltransferase. Dwoskin et al reported that nicotine isomethonium ion inhibits 
dopamine uptake in rat striatal slices and discussed that this point as to be explanatory 
for inverse relationship between smoking and Parkinsonism (Dwoskin et al., 1992). 
They further discussed that their structural relationship to neurotoxin MPP+ may be 
indicative of a possible protective role of N-methylated nicotine metabolites against  
Parkinson‟s Disease. N-quaternary glucuronide is formed via glucuronidation of the 
nicotine by uridine diphospate-glucuronosyltransferase (UGT) enzymes (Seaton et al., 
1993) and 3 to 5% of the nicotine is known to be converted to this metabolite and 
excreted in urine. However, in later steps of nicotine metabolism, cotinine and trans-3‟-
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hydroxycotinine also shown to be glucuronidated and excreted in urine as cotinine N-
glucuronide and trans-3‟-hydroxycotinine O-glucuronide (Benowitz and Jacob, 1994; 
Byrd et al., 1992; Yamanaka et al., 2005b). Therefore, when cumulative effect is 
considered, glucuronidation becomes a major reaction in nicotine metabolism and 
enzymes catalyzing these conversions show extensive variation with differential 
contribution and selectivity (Berg et al., 2010; Kaivosaari et al., 2007; Kuehl and 
Murphy, 2003; Lessov-Schlaggar et al., 2009). UGT enzymes take part in metabolism of 
not only nicotine but also in elimination of other drug toxicities and xenobiotic 
compounds (Cecchin et al., 2009; Derby et al., 2009; Ritter, 2000; van der Bol et al., 
2010) . These metabolic reactions take place in liver. Nevertheless, different tissues, 
particularly colon, also have expression of UGT enzymes and interestingly were found 
to be responsive to nicotine or drug treatments in terms of up-regulation or down-
regulation of  UGT enzymes (Kaivosaari et al., 2007; Kaya, 2009). Furthermore, one of 
these enzymes, UGT1A6, was found to be strongly up-regulated, while UGT1A1, -A3, -
A4, -A5, A7, -A8, -A9 and –A10 were detectably up-regulated in SW620 colon cancer 
cells in response to serum starvation combined nicotine treatment (Kaya, 2009). 
Fifth metabolite is nornicotine, by oxidative N-demethylation of nicotine (Neurath et al., 
1991) and nicotine to nornicotine conversion was shown to be catalyzed by CYP2A6 
and CYP2B6 in human liver (Yamanaka et al., 2005a). The last one is 2‟-
Hydroxynicotine and this conversion is mediated by cytochrome P450 (CYP2A6) 
(Hecht et al., 2000). 
Although there are several carcinogenic compounds, such as nicotine and alkaloids in 
tobacco smoke, like N'-Nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-
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1-butanone (NNK), alcoholic derivative of the NNN (NNAL),  and their metabolites 
(Hecht, 2002; Hoffmann et al., 2001), there is no study established to our knowledge 
showing carcinogenic effects of nicotine metabolites mentioned above. Furthermore, 
these carcinogenic compounds have been shown to be converted to non-carcinogenic 
metabolites and interestingly some of these derivatives are nicotine metabolites, like 
norcotinine and 3'-hydroxynorcotinine (Hatsukami et al., 2004; Hecht, 2002; Upadhyaya 
et al., 2002), which are further subjected to reactions given for nicotine metabolism. The 
enzymes involved in nicotine metabolism and glucuronidation are listed in Table 1 
together with corresponding AffyIDs. 
Table 1: Major metabolites of nicotine and enzymes that take role in catalyzing those conversions. Human 
Affymetrix probe identifiers are given for HGU133Plus2 Chip. Adapted from Affymetrix website. 
Metabolite Enzyme catalyzing conversion 
from nicotine 
Affy IDs for enzymes/enzyme 
groups on HGU133Plus2 Affy 
Chip 
Cotinine CYP2A6, Aldehyde oxidase (AOX1) CYP2A6: 1494_f_at, 211295_x_at, 
207244_x_at, 214320_x_at 
AOX1: 205082_s_at, 205083_at 
Nicotine N-oxide flavin – containing monooxygenase 3 
(FMO3) 
206496_at, 40665_at 
Nicotine 
isomethonium (N-
methylnicotinium) 
ion 
indolethylamine N-methyltransferase 
(INMT) 
224061_at 
N-quaternary 
glucuronide 
diphospate-glucuronosyltransferase 
(UGT) enzymes 
208596_s_at, 215125_s_at, 
206094_x_at, 221304_at, 
221305_s_at, 207126_x_at, 
204532_x_at, 236597_at, 
208358_s_at, 237572_at, 232654_s_at, 
206505_at,  207958_at, 211682_x_at, 
235904_at, 219948_x_at, 207245_at, 
207392_x_at, 228956_at, 
216687_x_at, 217175_at, 232655_at 
Nornicotine CYP2A6, CYP2B6 CYP2B6: 217133_x_at, 206755_at,  
206754_s_at 
2’-Hydroxynicotine CYP2A6  
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1.1.4. NACHRS: Structure, function and localization 
 
The nicotinic acetylcholine receptors (nAChRs) are members of a superfamily of 
receptors involved in ligand-gated ion transmission in both neural and muscular systems. 
Together with cholinergic muscarinic receptors, neuronal nAChRs have central role in 
mediating ACh message transduction. Their role in mediating fast actions of ACh in 
neuromuscular junctions and nervous system is well defined (Arias, 1997; Changeux and 
Edelstein, 1998; Gaimarri et al., 2007; Gotti and Clementi, 2004; Lena and Changeux, 
1998). They have widespread expression in nervous system and they transduce 
cholinergic signals in many brain areas and peripheral ganglia. nAChRs mainly have 
pre-synaptic localization in central nervous system and modulate neurotransmitter 
release, nevertheless in some areas they are localized post-synaptically and mediate fast 
synaptic transmission (Dajas-Bailador and Wonnacott, 2004; Gotti and Clementi, 2004; 
Jensen et al., 2005). Although originally classified as “neuronal” and “muscular”, later in 
time they are found to be expressed in a wide range of tissues including muscle, 
lymphoid tissue, macrophages, skin, lung cells, vascular tissue, and astrocytes (Gotti and 
Clementi, 2004). Additionally, in previous studies we have shown colonic expression, in 
human SW620 colorectal cancer cells, and liver expression in zebrafish (unpublished 
data).  
nAChRs are composed of homo- or heteropentamers of subunits, which are classified to 
five groups: α, β, γ, δ and ε. γ, δ and ε subunits are usually thought to be auxiliary 
subunits and a nAChR is denominated according to its α and β content on the grounds 
that these two subunits are important for pharmacological specificity and sensitivity of a 
complete receptor (Luetje and Patrick, 1991). Ten α-type (α1-α10) and four β-type (β1-
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β4) subunits are identified in human to date, among which α1 and β1 are muscle type 
subunits and others are classified to be of neuronal type. All subunits have four 
transmembrane domains with an intracellular loop between third and fourth, and both 
amino- and carboxy-terminal portions are localized extracellularly.  
Five subunits are needed to build up a fully functional receptor, and receptor 
composition and subunit stochiometry is decisive for specificity and functionality. Only 
α7 and α9 subunits are capable of forming homopentamers, on the other hand receptors 
containing α2-α6 and β2-β4 subunits form only heteromeric receptors (Gotti and 
Clementi, 2004; Lindstrom, 2000). 
1.1.5. nAChRs and Cancer in Human 
 
Cholinergic signaling and nAChR involvement in several cancer types have been shown 
in previous studies  (Schuller, 2009), since these receptors regulate neurotransmitter 
release which in turn might activate release of different growth factors. For instance, α7 
homomeric receptors, shown not to be desensitized unlike heteromeric receptors (Kawai 
and Berg, 2001), release adrenaline and noradrenaline which in turn increases epidermal 
growth factor (Carlisle et al.), vascular endothelial growth factor (VEGF) and 
arachidonic acid (AA) (Heeschen et al., 2002; Wong et al., 2007). On the other hand, 
α4β2 heteromeric receptors stimulate γ-aminobutyric acid (GABA) release (Al-Wadei 
and Schuller, 2009), which has been shown to inhibit tumor growth in colon (Joseph et 
al., 2002), breast (Drell et al., 2003), lung (Schuller et al., 2008b) and pancreas (Schuller 
et al., 2008a).  
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There is not much known about the association of muscle type nAChRs, α1 and β1, with 
cancer. Only one study has shown increased expression of these subunits in non-small 
cell lung cancer (NSCLC) (Carlisle et al., 2007). However, both of these subunits are 
involved in congenital myasthenic syndrome with mutations (Garchon et al., 1994; 
Quiram et al., 1999).  
1.1.6. Nicotine and SW620 Cells 
 
Previously, our group have investigated the effects of nicotine on colon cancer cells 
under serum deprivation (0.1% FBS) and normal growth conditions (Kaya, 2009). In that 
study it was shown that, when treated with serum deprivation, 1μM nicotine affected 
KEGG pathways such as cell cycle, calcium signaling and MAPK, cell adhesion and cell 
communication pathways, glucuronidation metabolism, coagulation cascade, ribosomal 
genes and purine-pyrimidine metabolism genes. Furthermore, that study have revealed 
that nicotine had the ability to relieve the cell proliferation from serum deprivation-
induced suppression and saves the cells from starvation-induced apoptosis. However, 
that study also have shown that nicotine when given to cells under normal growth 
conditions (10% FBS) for 2 days did not demonstrate such an effect. A 2 day treatment 
can perhaps be considered acute whereas 7 and 14 day treatments are rather chronic. 
1.2. Levamisole 
 
1.2.1. Structure, Properties and Antihelminthic Mode of Action 
 
Levamisole, L-isomer of tetramisole, was originally discovered at Janssen 
Pharmaceutica in 1966 and it is a synthetic derivative of imidazothiazole 
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(HelminthInfections, 2010). Figure 2 is a drawing representing the chemical structure of 
levamisole. Levamisole is also a weak base, like nicotine, with pKa of 8.0 and generally 
sold as hydrochloride salt form on the market with a molecular weight of 241 grams per 
mole (Yakoub et al., 1995). Additionally, it is light sensitive and stable under ordinary 
conditions. It melts at about 230 to 233
o
C and is soluble in water (Yakoub et al., 1995). 
Levamisole has a broad use as an antihelminthic in livestocks since it eliminates 
parasitic worms by paralysis. Other than the agricultural use, given the fact that over 1 
billion people in the developing world are infected with intestinal nematodes (Bethony et 
al., 2006), levamisole is also important in solving public health problems. 
Levamisole binds to acetylcholine receptors and causes body-wall muscle 
hypercontraction, spastic paralysis, and ultimately death of parasites (Lewis et al., 
1987a; Lewis et al., 1987b). Levamisole is reported to be sensitive to receptors on 
nematode and that it does not activate the AChRs on the host (Rayes et al., 2004), and 
such difference was thought to be due, nevertheless biophysical similarities of receptors, 
to the pharmacological differences between the nematode and mammalian host. 
However, molecular basis of such specificity was not elucidated enough. In a more 
recent study, Boulin et al showed that levamisole-specific AChRs were different from 
those bind nicotine (Boulin et al., 2008) and this may explain the specificity as to be not 
at the species level but at the molecular level. Nicotinic and levamisole-specific 
acetylcholine receptors will be discussed in detail later. 
Figure 2: Chemical structure of levamisole. Adapted from (Roberts, IPCS INCHEM) 
11 
 
1.2.2. Metabolism 
 
Levamisole was found to have a fast absorption and metabolism in humans after oral 
administration so that unchanged drug peak was reported to be reached 2h after dosing 
of 
3
H-levamisole while at this time about 60% of the radioactivity was reported to be 
found in the form of metabolites (Roberts, IPCS INCHEM). Levamisole is extensively 
metabolized in humans and only about 4 to 5% is excreted unchanged. Experiments on 
levamisole metabolism were performed generally on isolated hepatocytes of dogs, sheep, 
cattle, pigs and human; and some on rats and monkeys. One of the two major pathways 
is dehydrogenation and subsequent sulfoxidation of the imidazolidine ring, while the 
second being aromatic hydroxylation. This p-hydroxy levamisole has a glucuronide 
conjugate and together they make up to 17% of the administered levamisole. These 
experiments were performed in Janssen Research Foundation and submitted to World 
Health Organization (WHO) as unpublished experimental and preclinical reports 
(Roberts, IPCS INCHEM). 
1.2.3. L-AChRs: Structure, function, localization 
 
L-AChRs (levamisole-sensitive AChRs) are acetylcholine receptors sensitive to 
levamisole and similar to nAChRs, they are ligand gated ion channels functioning as 
pentamers. These receptors have greatly been studied in worm species, especially in 
nematode C. elegans where most of the information about them came from. C. elegans 
has the most extensive subunit variation of acetylcholine receptors with 27 subunits 
identified and provided on WormBase, 10 of which were identified from levamisole-
resistance or neuronal degeneration studies and 17 from functional genomics studies 
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after completion of its genome sequencing: unc-63/lev-7, unc-38, deg-3, des-2/acr4, 
acr5-12 and acr15-24 are alpha type; unc-29, lev-1, acr2, acr3, acr14 and acr25 are 
non-alpha type subunits (Ballivet et al., 1996; Baylis et al., 1997; Fleming et al., 1997; 
Jones and Sattelle, 2004; Mongan et al., 1998; Mongan et al., 2002; Squire et al., 1995; 
Treinin and Chalfie, 1995; Treinin et al., 1998; WormBase, 2010). Other than these 
AChR subunits, ric-3 (Halevi et al., 2002; Halevi et al., 2003), unc-50 (Eimer et al., 
2007) and unc-74 (Lewis et al., 1980) are found to be required for in vivo expression of 
L-AChRs. 
In C. elegans neuromuscular junctions, excitatory neurotransmission is mediated 
by L-AChRs and UNC-29, UNC-38 and UNC-63 were found to be absolutely required 
for a functionally active receptor (Boulin et al., 2008; Culetto et al., 2004; Fleming et al., 
1997; Lewis et al., 1987b; Rayes et al., 2007). 
One of the key points for safe usage of levamisole as medical and agricultural 
antihelmintic is the discrimination between the parasite and the host receptors. 
Acetylcholine receptors of human and other mammalians were investigated for 
levamisole sensitivity and levamisole was found to be a weak agonist of human nAChRs 
(Levandoski et al., 2003; Rayes et al., 2004). Another study revealed that nicotine-
sensitive and levamisole-sensitive receptors of C. elegans were insensitive to the ligands 
of each other (Boulin et al., 2008). Taken together, the data raised questions about the 
efficacy of levamisole in medical considerations other than soil transmitted helminth 
infections and antiparasitic in livestocks.  
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Two most important of medical conditions treatment with levamisole might be 
relevant to are nephrotic syndrome and adjuvant treatment of colon cancer in 
combination with 5‟ fluorouracil. While levamisole could not strongly activate human 
nAChRs, how it could have systemic effects, such as remission of edema, oliguria 
(Dayal et al., 1994), disappearance of proteinuria in nephrotic syndrome (Rashid et al., 
1996), increase in disease free and overall survival in colorectal cancer (Laurie et al., 
1989; Moertel et al., 1990),  in human is still a mystery.  
Furthermore, despite levamisole effect on these diseases in human was 
successfully shown in many studies, limitations of both success-showing and failure-
showing studies and additional inconsistencies between the limitations of those studies 
has made the issue much more complicated. Therefore, research of how levamisole 
exerts its effect on mammalian cells and systems has been overshadowed among the 
debate of presence or absence of such effect.  
1.2.4. Levamisole and Apoptosis 
 
In addition to antihelmintic activity of levamisole, it was also shown to act as an 
apoptosis inducer. Investigation of such a role for levamisole was motivated by its usage 
in colorectal cancer chemotherapy, which will be discussed later in this study, as an 
adjuvant in combination with 5-Fluorouracil. One of the most detailed studies came from 
Artwohl et al in 2000 (Artwohl et al., 2000). In this study, levamisole at 0.5 mM, 1 mM, 
2 mM and 5 mM concentration levels was shown to be a strong apoptotic inducer in 
human umbilical vein endothelial cells, adult human venous endothelial cells, and 
human uterine microvascular endothelial cells; but not in fibroblasts. One study with 
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human hepatoblastoma (HepG2) cells shows that levamisole, by being an activator of 
cystic fibrosis transmembrane conductance regulator (CFTR) Cl
-
 channels, inhibits the 
apoptosis induction by glibenclamide (Kim et al., 2001), which was also shown to 
induce apoptosis by inhibiting CTFR Cl
-
 channels in HepG2 cells (Kim et al., 1999). 
Taken together, levamisole might have a controversial association with apoptosis and/or 
apoptotic machinery. It appears levamisole is actually not an apoptotic or anti-apoptotic 
agent per se, but may be involved in the process in a very indirect manner depending on 
the context of apoptosis (intrinsic or extrinsic pathways), on the receptor status of the 
cell for levamisole, and on the dose of application, and finally on the cell type itself. 
Such an interpretation is also in line with the fact that there is no study established to our 
knowledge that could able to show a more direct interaction between any of the 
components of central apoptotic machineries and levamisole. 
1.2.5. Levamisole, Colorectal Cancer and Cell Proliferation 
 
Levamisole was considered for adjuvant chemotherapy for colon cancer in combination 
with 5‟Fluorouracil and it this chemotherapy was offered as standard for especially late 
stage colorectal cancer cases by National Cancer Institute Consensus Conference in 1990 
(NIH_Consensus_Conference, 1990). Studies for levamisole usage in colorectal cancer 
therapy started after 1990 and have mostly been based on two studies, preceding the NIH 
Consensus Conference (Laurie et al., 1989; Moertel et al., 1990). Levamisole has been 
tried for immunomodulatory effect in colorectal cancer since its immune enhancing 
effect had been appreciated already (Dahl et al., 2009; Laurie et al., 1989; Leibovici et 
al., 2009). Levamisole‟s effect on cell proliferation is also based on findings showing an 
enhancement of Th1 immune response and increased number of natural killer (NK) cells 
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(Holcombe et al., 1998; Zhang et al., 2009). However, there had been many studies 
unable to verify an efficient role for levamisole either in disease free survival (DFS) or 
overall survival (OAS) in colorectal cancer (Cascinu et al., 2003; De Placido et al., 2005; 
O'Connell et al., 1998). At the end, the role of levamisole in colon cancer treatment 
remained inconclusive, and it was withdrawn from clinical usage. After 2003, Jansen-
Cilag, pharmaceutical company that discovered levamisole in 1960s and produced since 
then, decided to stop production of ergamisol, the brand name for levamisole, for clinical 
usage (Davin and Merkus, 2005). Indeed, there is a need to decipher the role of 
levamisole, which had been frequently used as an adjuvant therapy, without knowing 
downstream molecular effects. 
1.2.6. Levamisole and Nephrotic Syndrome 
 
Levamisole has been tried for steroid-sparing effect in nephrotic syndrome (Davin and 
Merkus, 2005; Tanphaichitr et al., 1980), which is a disorder with protein loss from 
blood to urine, with damaged kidneys.  Since nephrotic syndrome treatment widely 
includes corticosteroids, with adverse effects in steroid-sensitive patients with nephrotic 
syndrome. Based on the study by Tanphaichitr et. al in 1980, levamisole was studied for 
sparing steroid from disease treatment, in other words, for reducing the steroid content of 
treatment. Although this issue has also remained inconclusive and overshadowed by the 
debates of presence or absence of a sufficient effect, there has not been any study to date 
questioning why levamisole should have such effect if any, and what could be the 
relationship between steroid metabolism and levamisole. 
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1.3. Microarray Analysis Methods 
 
1.3.1. Microarray Analysis Programs Based on R Environment 
 
Microarray studies have become widespread and enormous amounts of data have 
emerged and continue to do so.  It is crucial for a transciptomics dataset to be correctly 
preprocessed, analyzed and interpreted since the quality of these steps has decisive role 
in making the findings of the study meaningful. The flourishing of microarray 
experiments as a high throughput method has brought the necessity of designing tools 
for helping in handling and statistical evaluation of such large datasets, and functional 
interpretation of biologically relevant findings. 
R, an open-source programming language and environment developed for statistical 
computing and graphics, provides a nice opportunity and beneficial means for analysis 
of microarray data (R_Development_Core_Team, 2010). Nevertheless, R has a script 
based environment and its interface, like all other programming environments, might be 
difficult to handle for inexperienced users without adequate mathematical, statistical and 
computational background. Such difficulties create the need for design and production of 
customized routines and/or software to ease analysis steps. Therefore, R has a unique 
place since it contains a large array of packages geared for microarray preprocessing and 
analysis, although others exist that are based on C, Java, and Matlab®. 
Most of the web based services designed to perform multistep microarray analysis 
service provide mostly the statistical analysis of the data, with fixed parameters or with 
limited parametric options (http://crcview.hegroup.org, 
http://sourceforge.net/projects/geckoe). The quality control assessments of the arrays may 
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always not be included in such analyses; yet quality control is of special importance 
because if any of the arrays is poor in quality then it exerts a bias on the following 
statistical analyses. Such shortcomings and fragmentation of the whole analysis makes 
working on such high throughput datasets tedious; thus customized routines written in R 
and geared toward the user‟s own experimental design and analysis requirements are 
usually needed. 
One of the array analysis software based on R is BRB Array Tools, developed by 
Richard Simon and BRB-Array Tools Development Team, and works as an add-in with 
Microsoft© Excel® interface. This tool utilizes an Excel® frontend, which cannot be 
run under a Linux/Unix system, whose use might provide additional flexibility in 
integration of customized R routines into the analysis packages and larger memory 
options. In addition, functional analyses provided by BRB tools do not include gene 
network visualization. Other efficient R-based tools include Bionforx 
(http://bioinforx.com/), which is proprietary, WebArray (Wang et al., 2009; Xia et al., 
2005; Xia et al., 2009), EMAAS (https://www.emaas.org/EMAAS/), CARMAweb 
(Rainer et al., 2006); these serve the users online. Finally Babelomics team also employ 
a comprehensive microarray analysis service in their website based on analysis of gene 
lists, with Babelomics version 4.0 (www.babelomics.org). All of these tools and services 
are based on R environment and make use of BioConductor Project packages, especially 
in normalization and statistical analysis steps. Although such tools available and highly 
useful, having a customized R-routine to the user‟s experimental design, which is also 
modular and expandable, makes possible to add the most appropriate statistical design, 
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visualization and analysis tools as well as the recent algorithms and packages available 
in R environment.  
1.3.2. BioConductor 
 
BioConductor (www.bioconductor.org) is a software project with open source and open 
development features, and designed to produce tools for high-throughput genomic data 
analysis (Gentleman et al., 2004). Being primarily based on R programming language, 
most important part of the project is that it is composed of purposive R-packages, which 
can be downloaded via BioConductor‟s website and installed into R library. By 
definition a „package‟ is designed to include related software components and 
documentation for purposive objectives. Packaging system is well established in R and 
provides independent yet interoperable modules for usage in high-throughput data 
analysis to achieve various statistical analytic tasks and for visualization purposes. On 
the other hand, BioConductor provides annotation data packages, which ease mappings 
between different identifiers, such as affy IDs and Entrez genes, and such service 
enables association of array data to biological metadata from web databases. These 
annotation tools are beneficial for assembling and processing genomic annotation data 
from GenBank, Entrez genes, Unigene, Gene Ontology (GO) Consortium and USCS 
Human Genome Project. Since Bioconductor is an open source environment, microarray 
analysis packages available within the environment that range from quality control to 
differential expression and to functional analyses, can be easily integrated into the 
custom routines written in R. 
1.3.3. Functional Analysis of Microarrays Using Online Software 
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Once microarray data has undergone processing procedures and statistical analyses, 
functional analyses of the genes that have been identified to be differentially expressed 
should be performed. This step is of crucial importance on the grounds that only then the 
holistic impact of the experiment on the cellular response could be evaluated. Questions 
regarding the cellular processes and pathways that are influenced from the experiment 
find their answers with the comprehensive functional analyses that allow a more 
complete understanding of the nature of the experiment. 
There are several online software tools concerning functional analysis, all of which 
incorporate either Gene Ontology (GO) information or Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways or enrichment analysis with predefined or customized 
gene sets. Some of these services are provided by DAVID 
(http://david.abcc.ncifcrf.gov/), WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/), 
PathwayMiner (http://www.biorag.org/), GSEA (http://www.broadinstitute.org/gsea/), 
GSEA Molecular Signature Database (http://www.broadinstitute.org/gsea/msigdb/), 
Babelomics (www.babelomics.org), Ingenuity (http://www.ingenuity.com/).
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2. AIM of THE STUDY 
 
This study uses microarray analyses methods to understand the differences and 
similarities between the levamisole and nicotine, two of the cholinergic agents with 
medical implications, on the SW620 colon cancer cells. 
Here in this study we aim to assess the influences of these two agonists of nAChRs on 
human cells in terms of transcriptome profiling and the interpretation of functional 
implications and indications based on their differential and similar responses. Although 
thought as a therapeutic agent in several human disorders including colorectal cancer 
and nephrotic syndrome, levamisole has previously not been investigated for its effect at 
the cellular level. Furthermore, there exists no study established to our knowledge 
assessing the effects of levamisole on global transcriptional profile of the cells. Given 
the fact that efficiency studies on disorders, for which levamisole has been concerned as 
a therapeutic agent, remained inconclusive, we believe that our study will shed much 
light to comprehend an exact role for levamisole in treatment of those disorders at the 
dose specified in our experiments. On the other hand, we approached to the issue with a 
comparative manner and we compared and contrasted the effects of levamisole with 
nicotine; this approach is sound because inasmuch as both compounds are agonists of 
nAChRs, there is not a levamisole-sensitive receptor subset in humans. Furthermore, 
nicotine is known to have different effects upon acute or chronic exposure. Previous 
studies (Onur Kaya, 2009 Ms. Thesis) in our lab showed that a short term treatment of 
SW620 cells with 1μM nicotine did not result in large numbers of genes being 
differentially regulated. Therefore, we set out to test the effects of nicotine and 
21 
 
levamisole for an extended period of 7 days at which the exposure could be called 
chronic (Pakkanen et al., 2006; Sun et al., 2003).  
For data analysis, a customized R-routine was written using the available resources in 
BioConductor and related R packages to perform an automated analysis of one-factor 
experimental design of Affymetrix arrays (or any single-channel data) with two or more 
groups; the aim was to perform the analyses  from the very beginning to the end, 
seamlessly; so the steps included routines for array quality control assessment, 
differential expression, functional analysis and annotation, in a streamlined manner. We 
provide a generic implementation to enable the usage of the routine in any expression 
data independent of the number of groups. Results are generated in R and saved to a user 
defined directory with a given denomination extracted from the experiment descriptor 
file. Accordingly, we aim to provide a useful, strong and easily handled and expandable 
tool for researchers inexperienced in the analysis of large datasets; for the experienced 
ones we aim to provide additional flexibility with several options in analysis parameters. 
In general, our study aims to i) provide a streamlined routine for the analysis of one-
factor experimental design of Affymetrix arrays using R programming language; ii) to 
generate list of genes similarly modulated by nicotine and levamisole; iii) to generate list 
of genes differentially modulated by nicotine and levamisole; iv) to perform functional 
analyses on these lists by the provided routine and finally v) to confirm the expression 
pattern obtained from array data of selected genes using real-time polymerase chain 
reaction (PCR) in SW620 cells exposed to levamisole or nicotine.
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3. MATERIALS AND METHODS 
 
3.1. Levamisol and Nicotine Treatment of Cells for Microarray and RT-
PCR analysis 
 
SW620 colon cancer cells were seeded into the 75 cm
2
 flasks with a density of 1x10
6
 
cells per flask in DMEM supplemented with 10% fetal bovine serum (FBS) and 0.1% 
penicillin/streptomycin (P/S) mixture. Cells left for 24h for attachment to the plate and 
then medium was replaced with 0.1% FBS-containing medium to make cells quiescent 
(synchronization). Media then were replaced with fresh media that contain 1 μM 
nicotine- or 1 μM levamisole Media with treatments were replenished every 3 days. 
Cells incubated at 37
o
C with 5% CO2. Cells were gathered from the plates at day 7 or 15. 
For detaching cells from plate, trypsin/EDTA was used which was then neutralized by 
growth medium. Cells were centrifuged at 1200 rpm for 3 minutes, washed with PBS 
and stored at -80
o
C. Microarray optimizations, cell culture experiments and sample 
preparations were performed by Onur Kaya, a former MS student at Bilkent University. 
3.2. RNA extraction, cDNA synthesis and real-time PCR experiments 
 
RNA extraction was performed with Promega SV Total RNA Isolation Kit according to 
the manufacturers protocols except for some of the cases, a second DNAse treatment 
step preceding elution was added (Z3100; Madison, USA). cDNA synthesis was 
performed with Fermentas RevertAid™ First Strand cDNA Synthesis Kit (K1631; 
Lithuania). For confirmatory real-time PCR experiments, DyNAmo HS SYBR Green 
qPCR Kit from Finnzymes (F410L, Espoo, Finland) was used and experiments were 
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carried on Bio-Rad iCycler machine. Primers were designed with Primer 3.0 (Rozen and 
Skaletsky, 2000). Real time PCR conditions for all primers were as follows: 95
o
C 10 
min; 45 cycles 95
o
C 30 s, 60
o
C 30s, 72
o
C 30 s; 72
o
C 10 min. Real-time PCR experiment 
data were analyzed with Pfaffl method: ratio=[(Etarget)
deltaCt target (control-treated) 
/ (Eref)
deltaCt 
ref (control-treated)
] (Pfaffl, 2001); reference gene was chosen as beta-actin, which showed no 
difference both in our microarray data and real time PCR experiments. 
Table 2: Sequences and efficiencies of the primers of the genes selected for confirmatory real-time PCR 
experiments. 
Gene Primer Sequence Primer Efficiency 
ACTB 5' CCAACCGCGAGACGATGACC 3' 1.99 
 5' GGAGTCCATCACGATGCCAG 3'  
GULP1 5' CAGGCAGTATGACACCTAAG 3' 2.34 
 5' CAGGTCCCGTTTAATCTCAG 3'  
CHRNA1 5' GGCATCAAGTACATCGCAGA 3' 2.18 
 5' TCAATGAGTCGACCTGCAAA 3'  
CHRNB1 5' CCTGACGTGGTGCTACTGAA 3' 2.18 
 5' CAGCTGCTGCGATAGATGC 3'  
MKI67 5' GTGTCAAGAGGTGTGCAGAA 3' 2.28 
 5' GCCTTACTTACAGAATTCAC 3'  
XIAP 5' TCACTTGAGGTTCTGGTTGC 3' 2.22 
 5' CGCCTTAGCTGCTCTTCAGT 3'  
FOSL2 5' GGCCCAGTGTGCAAGATTAGCC 3' 2.03 
 5' TTTCACCACTACAGCGCCCACC 3'  
MAP1B 5' GTTGGAAGGAAAGGCTCAGT 3' 1.99 
 5' CTTGCTGTTTCTCATGGGTC 3'  
 
3.3. Microarray experiments 
 
Affymetrix GeneChip® U133 Plus2 arrays were used for sample hybridization; and 5μg 
RNA were used for each experiment (amplification/labeling/hybridization). Three 
different conditions were used for microarray experiments: 1) 1μM 7 days nicotine 
treatment, 2) 1μM 7 days levamisole treatment and 3) control; each group included two 
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replicates. Amplification, labeling and hybridizations were performed at the Genomics 
Core Facility of Bilkent university by the facility technician Bilge Kılıç under the 
supervision of Assoc. Prof. Dr. Işık Yuluğ according to the manufacturer‟s protocols. 
GeneChip Operating Software was used for preliminary probe-level quantification as 
previously described (Kaya, 2009). 
3.4. Quality Controls and Pre-processing of the microarray data 
 
For quality control and normalization of the data and for the determination of the 
differentially expressed genes followed by functional analysis, a streamlined R-routine 
was written (See Appendix). This R-routine basically has been composed of three 
different modules, first of which performs the quality control steps and data 
normalization (QualCont) while the second identifies differentially expressed genes 
(DEGidentifier) and the third performs functional annotation and analysis of the results 
(FuncAnn) (Figure 3). All three modules extensively use BioConductor packages (Figure 
4) (www.bioconductor.org). 
QualCont reads the data in from .CEL files provided with a phenodata file, an 
experiment descriptor file created by the user in a tab delimited text format, uploaded 
from a given directory. QualCont applies to the raw dataset a user-selected 
normalization method (i.e., RMA, gcRMA or MAS5) using the affy package (Gautier 
et al., 2004) and generates files containing normalized results in a spreadsheet as well as 
image formats. The function also assigns some of the results into the global environment 
of R to make some of the results readily available to the user for further analyses in the 
following modules. The R packages used in the QualCont function are affy (Gautier et 
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al., 2004) and affyPLM (Bolstad, 2004; Bolstad et al., 2005; Brettschneider et al., 
2007). QualCont function outputs include: photo images of the chips, normalized data 
files, histogram representation of the data distribution for the raw and normalized data, 
MA plots of the raw and normalized data and boxplots of raw and normalized data, and 
RNA degradation plot of the data (Figure 4). The function saves all these information in 
the directory provided by the user as the primary input to be used in other functions. 
3.5. Determination of Differentially Expressed Genes 
 
Differentially expressed genes were identified by the second function of the R-routine, 
DEGidentifier. This function has been designed as to apply a linear model and Bayesian 
statistics for the assessment of differential expression for one-factor randomized design 
experiment using the limma package in R (Smyth, 2005). 
Figure 3: Workflow of the routine. The routine is composed of three modules, each of which is 
composed of related functions. At each step, results are automatically saved to the user-defined 
directory, with appropriate denomination. 
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Accordingly, the contrast groups are formed also by the function based on the 
experiment description phenodata file, location of which is provided by the user. 
Normalized data are then fitted to a linear model for each gene, and estimated 
coefficients and standard errors are computed and finally differentially expressed genes 
are determined by empirical Bayesian methods. The R packages used in DEGidentifier 
module are: affy (Gautier et al., 2004), limma (Smyth, 2005) and 
hgu133plus2.db (Carlson et al., R package version 2.4.1). 
DEGidentifier provides differentially expressed genes between all paired groups in a 
given dataset and saves the retrieved information in different spreadsheets to a user 
defined directory. Outputs of the function are as follows: All probesets with significant 
differential expression between any two groups, separate up- or down-regulation lists for 
probesets, log-fold change of the intensities between groups. Additionally, it generates 
all the lists given above at the gene symbol level as well as at probe level, and creates 
Venn diagram and Heatmap representations for the comparisons between groups (Figure 
13, Figure 14). 
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Figure 4: Detailed schematic view of routine components. Input values and output results for each function as well as used BioConductor packages are given. Additional Custom functions 
ChartPlotter and PlotCharts are two functions modified from equivalent functions of package GeneAnswers (Feng et al., 2001). Those modifications were necessary for us to ensure streamline 
flow of the routine. 
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3.6. Functional Annotation and Analysis of Differentially Expressed Genes 
 
The third module of the R-routine, FuncAnn, performs functional annotation for 
differentially expressed genes in terms of Gene Ontology and KEGG (Kyoto 
Encyclopedia of Genes and Genomes) Pathways (Figure 17-Figure 21 and Figure 24; Table 
6-Table 9).  FuncAnn is composed of four different functions, KG_HyperG, GO_HyperG, 
KEGGscript and Grapher, written by us and two functions, ChartPlotter and 
PlotCharts, modified from the GeneAnswers package of BioConductor (Feng et al., 
2001). This module makes use of following BioConductor packages: KEGG.db 
(Carlson et al.), KEGGgraph (Zhang and Wiemann, 2009), GeneAnswers (Feng et 
al., 2001) and RGraphviz (Gentry et al.). 
KG_HyperG provides the results of hypergeometric testing of KEGG pathways in which 
the DEGs are involved. GO_HyperG function performs hypergeometric testing of GO 
terms for overrepresentation or underrepresentation of GO terms in a given significant 
probe list, independent of the chip platform as long as it is an Affymetrix human chip, in 
a given universal set of probe ids (default is all the probes defined on the chip). 
KEGGscript function generates outputs of detailed KEGG analyses of the results, 
separately for each contrast, where the name of the pathway, the coverage percentage of 
the pathway, the names of genes differentially expressed in that pathway and whether 
those genes are up-regulated or down-regulated are provided as output, by making use of 
KEGGgraph package of BioConductor. A table with the same information also is 
generated and saved to the working directory in spreadsheet format. Furthermore, we 
included graphical results for gene annotation within KEGGscript function. Top GO 
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processes and top KEGG pathways, to which the data are related, are provided as 
piechart and barplot, with the help of GeneAnswers package. Finally, Grapher 
function generates graphical results for KEGG pathways with directed edges and color 
code for up-regulation and down-regulation using KEGGgraph package of 
BioConductor. 
All the output of this module also is automatically saved into the working directory in 
easily readable plain text formats, spreadsheet formats or as images; all automatically 
denominated in accordance with the contrast groups (e.g.,. “levamisole-
nicotine_KEGGPathways.txt”).
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4. RESULTS 
 
4.1. Quality Control Assessment of Hybridization and Preprocessing of 
Microarray Data 
 
The QualCont program was applied to 6 microarray .CEL files that belong to 3 groups, 
nicotine, levamisole, and control. Each group contained 2 samples.  
QualCont (FilesPath,NormType,pdfile) 
Here FilesPath is the directory where .CEL files and experiment descriptor file (pdfile) 
are located. Since the function was designed as to read all available .CEL files in the 
given directory, it is important to create a separate folder for separate analyses. 
Furthermore, the directory given here is set as the working directory of the session, all 
the results are saved here from the beginning till the very end of the analysis. NormType 
is the normalization type (RMA, gcRMA or MAS5; all with lower letters) selected; and 
herein “rma” (Robust Multi-array Analysis) (Irizarry et al., 2003) was chosen as the 
normalization method. Pdfile is a descriptive text file explaining the experimental 
groups. 
Quality control analyses showed that there was no physical defect the on hybridized 
chips, like smears, (Figure 5) and all samples had similar RNA degradation slopes (Figure 
10), indicating that all the arrays were of adequate quality to be included in future 
analyses (Table 3).  
Histograms (Figure 6, Figure 7), boxplots (Figure 8) and  MA plots (Figure 9) of raw and 
normalized data were provided for comparison. Histograms demonstrated the signal 
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intensity distribution for the arrays. Post-normalization the distributions were more 
similar to normal distribution yet with a heavier right tail (Figure 7). Here we provide 
histograms, however Q-Q plots can also be very informative to see whether the signal 
intensity has normal distribution or not (R_Development_Core_Team, 2010). We should 
note here that for t-test assumptions, meeting of normality in distribution of signal 
intensities of “most probesets” across experiments is more important than satisfying 
normality of distribution of a single array, since we apply testing “between” arrays 
rather than “in” an array. Nevertheless, we found it useful to provide in-array-
distributions of signal intensities to get an idea about how general overview of signal 
distributions are seen in arrays. Additionally, it would be beneficial to keep in mind that 
with very low numbers of arrays (e.g. 6 in our data) it would not be easily possible to 
prove normality, since data with low sample size generally deviate from normal 
distribution. Thus use of tests such as limma are better suited for small sample size 
comparisons. Histogram representations were generated, denominated and saved 
automatically by the routine and hist function was used in the code. 
Another quality control measure is provided with the MA (MvA; M versus A) plots 
where one can get a quick overview of the intensity-dependent ratios of arrays. 
The basic assumption of microarray theory is that most of the genes do not show 
differential expression between the groups. For testing whether this assumption applies 
to a data we look for the ratios of signal intensities in arrays as pairs. According to the 
aforementioned rule, we expect to have mean of intensity ratios between arrays as 1 (0, 
when logged; log(1)=0). In a paired MA plot, this rule is visually checked as a quality 
control on the grounds that if there is much difference between two arrays, in other 
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words if the intensity ratio between arrays do not approximate to 1, that means the most 
of the genes in one of them shows differential expression. Such a result implies that the 
given array should be excluded from the analysis because it exerts a bias on the 
normalization procedure, which in turn leads to a bias in the statistical analytic steps.  
Therefore, in the streamline routine we included generation of MA plots of both raw and 
normalized data and we made use of mva.pairs function of affyPLM package of 
BioConductor. 
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Figure 5: Photographs of array chips. Images were created with the help of image function of the 
graphics package (R_Development_Core_Team, 2010). 
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Figure 6: Frequencies of signal intensities along arrays. The plot shows the distribution of the signal intensity 
before normalization. Images were created with the help of hist function of the graphics package 
(R_Development_Core_Team, 2010). 
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. 
Figure 7: Frequencies of signal intensities along the arrays after normalization. The plot demonstrates the 
new distribution of the data following normalization. Normalization procedure simply approximates the 
data distribution to normal distribution on the grounds that following tests and analyses are based on the 
assumption that the data is distributed normally. Images were created with the help of hist function of 
the graphics package (R_Development_Core_Team, 2010).  
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Figure 9 shows the MA plots of both raw and normalized data indicating all arrays pass 
this quality control. The y-axis represents the „M‟ component, intensity-ratio; x-axis 
represents the „A‟ component, average ratio for a dot in the plot. 
Figure 9 :MA Plots of arrays before and after  normalization (from left to right). M (y-axis) is the intensity ratio; A 
(x-axis) is the average intensity for a dot in the plot. MA plot provides a quick overview of intensity-dependent 
ratio. Images were created with the help of mva.pairs function of the affy package (Gautier et al., 2004). 
Figure 8: Box plot representation of data of each array before and after normalization. Represents intensity 
value distribution of arrays. To be analyzed together, all arrays should meet a very close mean value making 
the content comparable for differential expression analysis. y-axis shows signal intensity values (RMA 
normalization gives logged values of signal intensities). Images were created with the help of boxplot 
function of the graphics package (R_Development_Core_Team, 2010). 
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Figure 8 shows the boxplots of signal intensity distribution of arrays together pre- and 
post-normalization procedure. 
We made use of boxplot function for generation of the figures. To make arrays 
comparable for statistical testing, they are expected to have similar distribution of signal 
intensity values after normalization. We used empirical Bayes moderated t-test with 
Figure 10: RNA degradation plot of arrays. Represents the mean intensity for 5’ to 3’ probes. Each line 
represents an array within the data. Agreement of slopes of all arrays indicates good quality and allows 
all arrays to be analyzed together. Image was generated with the help of plotAffyRNAdeg function of 
affy package (Gautier et al., 2004). 
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linear regression model. This type of moderated t-test is different from classical types of 
t-test, since with empirical Bayes method the probe-wise sample variances are shrunken 
towards a common value and the degrees of freedom for the individual variances are 
augmented (Smyth, 2004). 
Next, RNA degradation profiles of the samples were subjected to quality control 
assessment, because high levels of RNA degradation lowers the hybridization and data 
quality, and biases the resulting expression profile. For this reason, we included 
generation of plots and tabularized reports for RNA degradation of arrays in the 
streamline routine. We used AffyRNAdeg, summaryAffyRNAdeg, 
plotAffyRNAdeg functions of affyPLM package. 
Table 3: Summary of RNA degradation information of arrays. Note that slopes of all plots are comparable and 
below 3, the value advised by Affymetrix as a maximum. P value is calculated by AffyRNAdeg function internally 
from linear regression of means by number. 
 O15-
7C1.CEL 
O18-
7C2.CEL 
O16-7N1.CEL O19-7N2.CEL O17-
7L1.CEL 
O20-
7L2.CEL 
slope 2.73 2.6 2.8 2.66 2.44 2.74 
pvalue 1.23E-12 6.44E-11 3.36E-12 3.45E-11 1.31E-09 7.72E-11 
RIN 7.7 7.8 7.7 8.1 7.7 7.9 
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Figure 10 shows RNA degradation plots of our six arrays. Ideally, without any RNA 
degradation, mean signal intensity would be flat from 5‟-to-3‟ direction, as RNA 
degradation takes place in 5‟ to 3‟ direction, and signal from all portions would be equal. 
However, in reality the situation is not so perfect that it is always possible to see RNA 
degradation to some certain level. What is more important than the presence or absence 
of the degradation itself is the agreement of slopes between all arrays, which means all 
arrays have the same level of RNA degradation and all could be used together in 
normalization and analysis steps. Therefore, we were able to conclude that all of the six 
arrays pass this criterion for analysis and there exists no problem related with the 
qualities of signal data and normalization steps, as it is understood from post-
normalization plots and RNA quality values and the RIN values (Table 3). 
Figure 11: RLE (relative log expression) plots of arrays. Image was generated with the help 
of RLE function of the affyPLM package (Brettschneider et al., 2007). 
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Finally, boxplots of the relative log expression, RLE plots (Moertel et al.) of the arrays 
was also generated by the routine for quality control assessment and arrays also passed 
that criterion as RLE plots of all have mean of  zero (Figure 11). RLE function of the 
affyPLM package was used for this purpose. 
4.2. IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES 
 
To determine differentially expressed genes, we used DEGidentifier function: 
DEGidentifier(ndata,pdfile,lfc,method,adjust.method,p.value) 
The function uses normalized data (ndata) and experiment description file (pdfile; 
column „Target‟ used for groups and contrasts definition) as raw material to work on. In 
our analysis of levamisole and nicotine, an lfc (log fold change) threshold was not set  
not to overlook a systemic response and to obtain a certain number of probesets for 
functional analyses. We selected method (multiple testing method) as “separate”, 
meaning that all contrasts were subjected to multiple testing separately, on the grounds 
that we tried here to answer independent questions by analyzing different contrasts 
Figure 12: Experiment descriptor (phenodata) file we used for our analysis. We provide a screenshot of 
the tab delimited text file in order to demonstrate how a phenodata file should be provided for proper 
working of function DEGidentifier. Function reads in the .CEL files in the same order with column 
‘FileName’ and makes pairs of which file belongs to which group in accordance with the order given in 
phenodata file. Since the group contrasts are made automatically by the routine according to the 
experiment description provided by the user, it is crucial to provide a properly prepared one to get 
reliable results. 
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(please see “Limma User‟s Guide” for details). For adjust.method (multiple testing 
correction method) we preferred “none”. There are a number of reasons for such preference. 
First and the foremost, multiple testing correction methods are applied to lower the possibility of 
Type I error (false-positive results) running the risk of losing true-positive results. When we 
applied Bonferonni (“BF”) or Benjamini&Hochberg (“BH”) correction methods we lose 
power because of small sample size. Therefore, we chose not to apply a multiple 
correction method but set a significance threshold relatively low, i.e., p≤0.01 
(p.value). This value corresponded to a 27% FDR for nicotine-control comparison, 
and 26% FDR for levamisole-control comparison. Testing was performed following a 
linear model fitting and empirical Bayesian moderation. lmFit, contrasts.fit, 
eBayes and decideTests functions of limma package were used. Results were 
explained below. 
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4.2.1. NICOTINE AND LEVAMISOLE ACT SIMILARLY ON SW620 COLON 
CANCER CELLS 
Overall, 3088 probes were found to be differentially expressed between any two groups 
(p≤0.01) (Figure 13). Nearly 2100 probesets showed differential expression in response 
to levamisole and about the same number in response to nicotine. Interestingly, over 
1200 of affected probesets were shared by nicotine and levamisole, and behaved  in the 
same manner (i.e., up- and down-regulated in both) when compared to control samples 
(Figure 15 and Figure 16). On the other hand, about 200 probesets were affected 
differentially between the nicotine- and levamisole-treated groups. Accordingly, 
unsupervised hierarchical clustering showed that nicotine and levamisole groups were 
clustered together, while contrasting with the control group samples (Figure 14). When 
the genes with differential expression were grouped in terms of the direction of the 
response, it was obvious that about 60% of the affected genes responded with up-
regulation in both levamisole and nicotine treatment as compared to control group. 
Figure 13: Venn Diagram representation of probe numbers with significant differential expression between 
the given groups (p≤0.01). Diagram obtained by the routine with VennDiagram function. 
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Table 4: Table showing the number of probes differentially expressed between groups. (*) Gene numbers are 
obtained by ID conversion. Probe IDs with no known gene symbols (NAs) are removed from gene lists. 
Therefore it might be possible to suggest that chronic nicotine or levamisole exposure on 
the SW620 cells had rather up-regulatory role than down-regulatory. 
Comparison Up-regulated 
Probe/Gene* 
Down-regulated 
Probe/Gene* 
Sum 
Probe/Gene* 
levamisole-control 1275/837 832/558 2107/1395 
nicotine-control 1297/833 753/511 2050/1344 
nicotine-levamisole 254/153 30/22 284/175 
Figure 14: Heatmap generated with the expression values of significantly differentially expressed genes. Note the 
similarity between the levamisole- and nicotine-treated samples (p<=0.01) while both are contrasting with control 
samples. Red color: up-regulation; Blue color: down-regulation. Picture generated by the routine using heatplot 
function of the package made4 (Culhane).  
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A few group of genes, differentiating nicotine response from levamisole response, were 
largely (87-89%) subjected to up-regulation by nicotine treatment (Table 4). The 
percentages given also were similar when probe-to-gene conversion was made. 
Table 5: Detailed numbers of probes differentially expressed between groups. 
 levamisole-control nicotine-control nicotine-levamisole 
2+ fold UP 11 18  
1-2 fold UP 248 316 46 
0-1 fold UP 1016 963 208 
0-1 fold DOWN 560 530 30 
1-2 fold DOWN 246 194  
2-3 fold DOWN 16 18  
3+ fold DOWN 10 11  
Detailed numbers of differentially expressed probes distributed to the difference clusters 
were given in Table 5. Interestingly, we found that moderate but not high levels of fold 
changes were seen in levamisole and in nicotine treatment. In both treatments about 75% 
of the differentially expressed probes responded in the range of 0-to-1 fold change in 
both directions. 
Figure 15: Fold change correspondence between gene groups affected by nicotine and levamisole in 
comparison with control. Image was generated with the help of plot function of the graphics package 
(R_Development_Core_Team, 2010). 
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4.3. FUNCTIONAL ANALYSIS 
 
Functional analyses of the data were performed with the help of FuncAnn module. This 
third module is composed of six different functions: GO_HyperG, KG_HyperG, 
KEGGscript, PlotCharts, ChartPlotter and Grapher.  
GO_HyperG("BP", conditional=TRUE, AllSignifProbes, 
universe_GeneIds=NULL,categorySubsetIds=NULL, 
"hgu133plus2.db", 0.05, "over") 
KG_HyperG(AllSignifProbes, universe_GeneIds = NULL, 
"hgu133plus2.db","KEGG", 0.05, "over") 
Figure 16: Fold change correspondence between gene groups affected by either levamisole (left) or by 
nicotine versus gene groups that differ between nicotine and levamisole. Image was generated with the help 
of plot function of the graphics package (R_Development_Core_Team, 2010). 
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GO_Hyper and KEGG_Hyper are designed to perform hypergeometric tests for over- 
or under-representation of GO terms and KEGG pathways, respectively. Results are 
saved to the working directory in spreadsheet or plain text formats. 
KEGGscript(results) 
KEGGscript maps all the significant DEGs to the available pathways and provides a 
detailed result file informing which of significant DEGs are mapped to any KEGG 
pathway and at what percentage. Although KG_HyperG performs a similar job with a 
user-defined p-value, KEGGscript provides virtually all pathway information of the 
results. We believe such information would be useful particularly for the assessment of a 
systemic effect by the treatment. When numbers of genes in a given gene list are 
represented in a pathway with low percentage, it is eliminated in complete pathway 
testing, because such gene testing approach will require as many genes in the pathway. 
However, if the treatment affects many pathways, nonetheless with low coverage 
percentages, it could be considered for a systemic effect. Therefore, for a more systems 
biology geared approach, KEGGscript would be beneficial. 
PlotCharts is the subfunction of ChartPlotter and the latter is employed in 
KEGGscript to plot graphical representation of distribution of top five GO and KEGG 
categories in significant gene lists. This plotting process were performed for each 
significant gene list of contrasts as well as for list of all significant DEGs in the data.  
Grapher generates the KEGG pathway graphs for all contrasts with color coded up- or 
down-regulation information and directed edges. This function has been designed to take 
three inputs: normalized data, fold-change data of significant DEGs and finally a vector 
of KEGG ids desired to be plotted. Plotting all of the KEGG ids found in the data is 
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unnecessary and brings much burden to the CPU. Therefore, we chose to generate 
graphs of KEGG pathways that were previously found to be significant in the KEGG 
Hypergeometric Testing and retained this as default list if the SignifKEGGIDs input 
is given as NULL. 
Table 6: Hypergeometric testing results of GO terms of genes differentially expressed in response to nicotine. 
Table is generated by GO_HyperG function. There were about 200 significantly overrepresented GO terms (see 
Appendix). Top 15 are provided here (p≤0.05). 
GOBPID Pvalue OddsRatio ExpCount Count Size Term 
GO:0006695 1.88E-05 6.137 2.507176674 11 33 cholesterol biosynthetic process 
GO:0006066 2.77E-05 2.389935846 15.50045893 33 207 alcohol metabolic process 
GO:0006694 8.14E-05 2.969618129 7.825430225 20 103 steroid biosynthetic process 
GO:0055114 0.00012371 1.673508435 45.73698054 71 602 oxidation reduction 
GO:0008654 0.000143128 2.924697581 7.521530022 19 99 phospholipid biosynthetic 
process 
GO:0043603 0.000186888 3.800505773 4.17862779 13 55 cellular amide metabolic 
process 
GO:0045017 0.000333598 3.025836877 6.153979109 16 81 glycerolipid biosynthetic 
process 
GO:0005996 0.000420841 2.049759986 17.09438641 32 225 monosaccharide metabolic 
process 
GO:0045007 0.000437342 Inf 0.227925152 3 3 depurination 
GO:0051186 0.000838224 2.094512195 14.13135943 27 186 cofactor metabolic process 
GO:0006006 0.001095333 2.199749988 11.52882808 23 152 glucose metabolic process 
GO:0048255 0.001130176 6.667571235 1.291575862 6 17 mRNA stabilization 
GO:0019320 0.001609768 2.899125524 5.166303449 13 68 hexose catabolic process 
GO:0009820 0.001685911 3.499643214 3.418877283 10 45 alkaloid metabolic process 
GO:0001568 0.00175715 1.78639481 21.65288946 36 285 blood vessel development 
 
GO term hypergeometric testing was performed with significant probes lists for nicotine 
and levamisole treatments with the help of GO_HyperG function. There was again a 
large similarity between nicotine and levamisole since both groups shared 141 of 191 
and 150 passed GO terms, respectively. Table 6 and Table 7 indicate the first 15 GO IDs 
of nicotine and levamisole. Similarities between most significant list can be listed as 
cholesterol biosynthetic, steroid biosynthetic and alcohol metabolic processes. 
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Table 7: Hypergeometric testing results of GO terms of genes differentially expressed in response to levamisole. 
Table is generated by GO_HyperG function. There were about 150 significantly overrepresented GO terms (see 
Appendix). Top 15 are provided here. p≤0.05. 
GOBPID Pvalue OddsRatio ExpCount Count Size Term 
GO:0048519 0.000140646 1.378847354 144.3841587 185 1779 negative regulation of biological process 
GO:0006695 0.000194961 4.958959772 2.678289622 10 33 cholesterol biosynthetic process 
GO:0006986 0.000357035 3.332277986 5.031938078 14 62 response to unfolded protein 
GO:0031324 0.000543165 1.527808823 57.29916585 82 706 negative regulation of cellular metabolic 
process 
GO:0048522 0.000706006 1.329330832 144.3841587 180 1779 positive regulation of cellular process 
GO:0016481 0.000832369 1.64242941 36.52213121 56 450 negative regulation of transcription 
GO:0051172 0.001285224 1.573932339 41.31058841 61 509 negative regulation of nitrogen compound 
metabolic process 
GO:0006613 0.001702696 8.119601329 0.973923499 5 12 cotranslational protein targeting to 
membrane 
GO:0032535 0.002056754 1.702379753 25.80897272 41 318 regulation of cellular component size 
GO:0010941 0.002345488 1.418551302 66.30795822 89 817 regulation of cell death 
GO:0051270 0.0032171 1.886022514 15.50161569 27 191 regulation of cellular component 
movement 
GO:0044282 0.00390167 1.790922619 18.01758473 30 222 small molecule catabolic process 
GO:0030968 0.004049797 4.873503591 1.623205832 6 20 endoplasmic reticulum unfolded protein 
response 
GO:0006066 0.004052468 1.805127235 17.28940529 29 215 alcohol metabolic process 
GO:0000122 0.004468916 1.720200573 20.53355377 33 253 negative regulation of transcription from 
RNA polymerase II promoter 
 
After we assessed the molecular and cellular processes affected by nicotine or 
levamisole treatments, we evaluated the specific reaction and/or gene interaction 
information with KEGG pathways in order to assess functional effects of the treatments 
in detail. We performed KEGG pathway hypergeometric testing with DEG of “nicotine 
vs. control” and “levamisole vs. control” comparisons. Each result included 13 different 
pathways and 11 of which were the same (Table 8). The most important part for us was 
molecular processes and pathways involved in steroid, lipid and cholesterol metabolisms 
as this finding was previously not shown in the literature to our knowledge.  
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Table 8: KEGG Pathways overrepresented in nicotine and levamisole data. Lists generated by KG_HyperG function 
(p≤0.05). 
Nicotine Levamisole Nicotine-Levamisole 
Glycolysis / Gluconeogenesis Glycolysis / Gluconeogenesis Galactose metabolism 
Citrate cycle (TCA cycle) Citrate cycle (TCA cycle) Steroid biosynthesis 
Pentose phosphate pathway Pentose phosphate pathway Oxidative phosphorylation 
Pentose and glucuronate 
interconversions 
Pentose and glucuronate 
interconversions 
Purine metabolism 
Fructose and mannose metabolism Fructose and mannose 
metabolism 
Valine, leucine and isoleucine 
degradation 
Galactose metabolism Galactose metabolism Starch and sucrose metabolism 
Ascorbate and aldarate 
metabolism 
Ascorbate and aldarate 
metabolism 
Amino sugar and nucleotide sugar 
metabolism 
Fatty acid biosynthesis Fatty acid biosynthesis Inositol phosphate metabolism 
Fatty acid metabolism Fatty acid elongation in 
mitochondria 
One carbon pool by folate 
Synthesis and degradation of 
ketone bodies 
Fatty acid metabolism Riboflavin metabolism 
Steroid biosynthesis Synthesis and degradation of 
ketone bodies 
Nicotinate and nicotinamide 
metabolism 
Primary bile acid biosynthesis Steroid biosynthesis Pantothenate and CoA 
biosynthesis 
Ubiquinone and other terpenoid-
quinone biosynthesis 
Primary bile acid biosynthesis Aminoacyl-tRNA biosynthesis 
  Metabolic pathways 
  RNA degradation 
  Basal transcription factors 
  Spliceosome 
  Proteasome 
  Protein export 
  Nucleotide excision repair 
  MAPK signaling pathway 
 
Although the significant number of DEGs in the levamisole-nicotine comparison was 
smaller than the other two,  over represented pathway number was much higher. Such 
results might arise because of testing of small gene lists. Nevertheless, keeping the p-
value lower can provide stringency with such small gene lists. 
As a third step in functional analysis part, we employed KEGGscript function providing 
detailed information in both a tabular and graphics format. KEGGscript uses all the 
KEGG information available from the data in these analyses (Table 8). According to 
these results about 60% of the genes in the steroid biosynthesis pathway were up-
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regulated with nicotine and about 50% was up-regulated with levamisole treatment. 
Other most affected pathways were: Terpenoid backbone biosynthesis, Limonene and 
pinene degradation, Propanoate metabolism, Valine, leucine and isoleucine degradation, 
beta-Alanine metabolism, Fatty acid biosynthesis Fatty acid metabolism, Biosynthesis of 
unsaturated fatty acids and synthesis and degradation of ketone bodies. 
Table 9: KEGG pathways effected by nicotine or levamisole treatment. All available KEGG pathways are evaluated 
in terms of genes and pathway coverage percentage values. Top results are provided here; for full result see 
Appendix. Table was generated by KEGGscript function. 
 
Names of the genes were provided in “***KEGG_RESULT.txt” files generated by 
KEGGscript for each comparison. Pathway coverage percentages were provided in 
spreadsheet files with “KEGG_TABLE***” denomination. 
GROUPS Levamisole- 
Control 
Nicotine-Control Nicotine-Levamisole 
PATHWAY NAME DOWN 
% 
UP % DOWN 
% 
UP % DOWN 
% 
UP % 
Steroid biosynthesis - 47.06 - 58.82 - 5.88 
Terpenoid backbone 
biosynthesis 
- 26.67 - 26.67 - - 
Limonene and pinene 
degradation 
- 25.00 - 25.00 - - 
Propanoate metabolism 3.03 24.24 - 24.24 - - 
Valine, leucine and 
isoleucine degradation 
- 22.73 - 20.45 - 2.27 
beta-Alanine metabolism 4.55 22.73 4.55 9.09 - - 
One carbon pool by folate 5.88 17.65 - 5.88 - 5.88 
Fatty acid biosynthesis - 16.67 - 16.67 - - 
Fatty acid metabolism - 16.67 - 14.29 - - 
Pyruvate metabolism 2.50 15.00 - 17.50 - - 
Pentose phosphate pathway - 14.81 - 18.52 - - 
Glycerolipid metabolism 4.08 14.29 4.08 18.37 - - 
Ubiquinone and other 
terpenoid-quinone 
biosynthesis 
- 14.29 - 14.29 - - 
Butanoate metabolism - 14.29 - 11.43 - - 
Biosynthesis of unsaturated 
fatty acids 
4.76 14.29 - 9.52 - - 
Thiamine metabolism - 12.50 12.50 12.50 - - 
Synthesis and degradation 
of ketone bodies 
- 11.11 - 11.11 - - 
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In addition to these, KEGGscript also provides graphics representation of top 5 
categories for both GO terms and KEGG pathways for the significant DEGs of each 
group and significant DEGs in all data. The number of genes covered, rather than the 
coverage percentage of a GO term pathway, is the determinant of ranking in these plots. 
For this visual support we made use of GeneAnswers package components and we 
modified two of functions, plot functions, in order to adjust them in the customized 
routine used in the present analysis. 
Figure 17 to Figure 21 examplified the GO and KEGG plots for upregulated and 
downregulated genes in nicotine and levamisole treatment, respectively. Similarity 
betwen the levamisole and nictine response was apparent in particularly the up-
regulatory sections. The most affected 5 GO terms and KEGG pathways by levamisole 
or nicotine were nearly the same. Shared GO processes were metabolic processes, small 
molecule metabolic process, lipid metabolic process and oxidation reduction processes, 
all of which were up-regulated by both nicotine and levamisole. KEGG pathways 
common to these treatments were metabolic pathways, valine, leucine and isoleucine 
degradation, steroid biosynthesis and propanoate metabolism. Fifth pathway in nicotine 
vs control group was the glutathione metabolism pathway while it was the fatty acid 
metabolism in the levamisole treatment. 
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Figure 17: Bar plots of top 5 categories in GO Biological Processes of DEGs up- or down-regulated by nicotine. Generated 
by KEGGscript function. ChartPlotter and PlotCharts functions are used for plotting. Function benefits from 
GeneAnswers package of BioConductor. a)GO Processes in up-regulated DEGs by nicotine; b) GO Processes in down-
regulated DEGs by nicotine. Images were generated by KEGGscript function with the help of ChartPlotter and PlotCharts, 
two functions modified from equivalent functions of GeneAnswers package (Feng et al., 2001). 
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Figure 18: GO Biological Processes of DEGs up-regulated by levamisole. Images was generated by KEGGscript function 
with the help of ChartPlotter and PlotCharts, two functions modified from equivalent functions of GeneAnswers 
package (Feng et al., 2001). 
Figure 19: Barplots of top 5 categories in KEGG Pathways of DEGs down-regulated by nicotine. Images was generated 
by KEGGscript function with the help of ChartPlotter and PlotCharts, two functions modified from equivalent 
functions of GeneAnswers package (Feng et al., 2001). 
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Figure 21: GO Biological Processes of DEGs down-regulated by levamisole. Images was generated by KEGGscript 
function with the help of ChartPlotter and PlotCharts, two functions modified from equivalent functions of 
GeneAnswers package (Feng et al., 2001). 
Figure 20: KEGG Pathways in DEGs up-regulated by levamisole. Images was generated by KEGGscript function with 
the help of ChartPlotter and PlotCharts, two functions modified from equivalent functions of GeneAnswers 
package (Feng et al., 2001). 
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Finally, Grapher function provides KEGG pathway graphics with up- or down-
regulation color code and directed edges. Basicly, KEGGgraph objects of pathways are 
visualized with this function. However, definition of attributes for color code and log-
fold change data is defined by via Grapher function so that the graph only becomes 
informative when plotted in an experimental context.  Pathways found significant from 
KG_HyperG function in any of the comparisons are plotted. 
The upregulated genes in the steroid biosyntheis pathway for all three comparisons were 
shown in Figure 24. This pathway was chosen as a representative since it has been one of 
the most significantly affected pathways. Pivotal enzymes in cholesterol synthesis from 
dehydrocholesterols, DHCR7 and DHCR24, and lanosterol synthase (LSS) catalyzing 
the first step in biosynthesis of cholesterol, steroid hormones and vitamin D,  were 
significantly upregulated in both treatments (Figure 24). 
4.4. CONFIRMATORY REALTIME PCR RESULTS 
 
We performed confirmatory real time quantitative PCR analyses with chronic (7 days) 
nicotine and levamisole treated SW620 cells for GULP1, CHRNA1, CHRNB1, MKI67, 
XIAP, FOSL2 and MAP1B, genes whose transcriptional responses were summarized in 
Table 10. We have selected these genes for confirmation experiments since these genes 
except CHRNB1 also seemed to be affected by 1μM  nicotine treatment in serum 
deprived SW620 cells in a previous study by our group (Kaya, 2009). Furthermore, we 
used additional set of samples with treatments of nicotine and levamisole for 15 days to 
see the effects associated with chronic use. The real time qPCR analyses for 7 and 15 
days were performed using an independent cell culture experiments; each day had a 
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single replicate, thus are preliminary in nature. Figure 22 shows the efficiency curves of 
the genes under investigation; the primer specific efficiencies were used in calculations 
of fold changes between control and treatment groups. 
Except the proliferation marker MKI67, we were able to confirm responses of all the 
selected genes to the treatments (Figure 23; Table 10).  Accordingly, GULP1 was 
drastically reduced as FOSL2, and MAP1B. XIAP was moderately reduced at day 7 
(Table 10). The fold change differences between the control and treatment groups in 
microarray experiments and realtime qRT PCR results from 7 and 15 day experiments 
were shown in Figure 23. The day 7 qRTPCR experiment was in concordance with day 7 
microarray results, as expected. At day 15, the changes observed at day 7 might be 
reversed except for CHRNA1 and CHRNB1. These results were obtained from one set 
of samples thus need to be repeated in future studies. 
Table 10: Fold changes of confirmation genes in microarray data and qPCR experiment. qPCR fold change values 
were calculated with ΔΔCt method (Pfaffl, 2001) and original results were logged. Note the similarity between 
profile pairs, except for MKI67. Correlation analyses between profiles from microarray fold-change and qPCR fold-
change were performed: for nicotine ρ = 0.9175, p-value = 0.0099; for levamisole: ρ = 0.9652, p-value = 0.0018. 
(MKI67 was excluded from correlation analyses). 
 Microarray Results qPCR results 
 1 μM Nic 1 μM Lev 1 μM Nic 1 μM Lev 10 μM Lev 
GULP1 -3.25 -3.09 -1.17 -1.04 -1.50 
CHRNA1 0.75 0.63 0.80 0.45 0.38 
CHRNB1 0.66 0.48 0.33 0.36 0.45 
MKI67 0.69 0.66 -0.35 -0.12 -0.04 
XIAP -0.10 -0.58 -0.14 -0.28 -0.49 
FOSL2 -1.03 -0.96 -0.53 -0.54 -0.77 
MAP1B -0.60 -1.18 -0.58 -0.36 -0.31 
 
CHRNA1 and CHRNB1, encoding two subunits of nAChRs involved in the congenital 
myasthenic syndrome, increased in expression in response to both of the treatments in 
the PCR experiments, in line with the microarray findings. Interestingly, no other 
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subunit expression difference was seen either in PCR experiments or microarray data, 
since it was previously reported that nicotine exposure had up-regulated nAChR subunit 
expression (Fu et al., 2009).  
XIAP, known to encode an anti-apoptotic gene and mediator of caspase-3 and -7 (Scott 
et al., 2005), decreased with chronic levamisole and nicotine treatments in the 
microarray data (Table 10) and this was confirmed with PCR experiments. Nicotine‟s 
anti-apoptotic ability by inducing XIAP has been shown in a previous study (Dasgupta et 
al., 2006). However, that study was not based on a chronic treatment and they used 36h 
samples. 
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Figure 22: Efficiency curves for primers of the selected confirmation genes. The x-axis shows logged values of 
relative concentration points of the cDNA samples (1000 for undiluted standard cDNA; 100 for 1:10 dilution; 
10 for 1:100 dilution and 1 for 1:10000 dilution)  and the y-axis shows the Ct values. 
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Decreases in FOSL2 and MAP1B were also confirmed with real-time PCR experiments. 
FOSL2 (FOS-like antigen 2; or Fra-2: Fos-related antigen 2), encodes a member of FOS 
family of proteins and was implicated in cell proliferation and differentiation an 
upstream regulator of AP-1 (Eferl et al., 2008). 
Figure 23: Confirmatory real-time results of given genes. All except MKI67 are in line with the microarray 
data findings (see Table 10 for correlation analyses results). 
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MAP1B, encoding a microtubule associated protein and known neuronal marker 
(Schoenfeld et al., 1989), was down-regulated upon chronic nicotine and levamisole 
exposure in both the microarray and 7 day qRT-PCR study reported here. 
GULP1, encoding engulfment adapter protein (Su et al., 2002), has been shown to be 
involved in clearance of cells undergoing apoptosis (Smits et al., 1999) during 
inflammation, and autoimmunity as well as embryonic development and normal tissue 
turnover. GULP1 expression decreased with nicotine and levamisole treatments. 
Furthermore, GULP1 showed a much more drastic decrease in expression when 
chronically treated with 10 μM levamisole. 
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Figure 24: Steroid biosynthesis pathway in group comparisons. Generated by Grapher function. Differences between the expression values and fold-change ratios are 
powerfully represented with supportive visual graphs. Grapher depicts the KEGG pathway information of a set of KEGG IDs, which is the union of separate subsets 
obtained from separate implementations KG_HyperG function for different comparisons. 
62 
 
5. CONCLUSION AND DISCUSSION 
 
This study uses microarray analysis methods to understand the differences and 
similarities between the levamisole and nicotine treatments on the SW620 colon cancer 
cells. The thesis aimed to A) to streamline an R-based routines based on existing and 
customized packages for the analysis of three group one-factor experimental design of 
Affymetrix arrays; B) to determine the genes commonly modulated by nicotine and 
levamisole; C) to determine the genes differentially modulated by nicotine and 
Levamisol; D) to perform functional analyses on these lists using our R-based routines; 
E) to confirm the expression pattern of selected genes using real-time RT-PCR of 15 day 
levamisole and nicotine-exposed SW620 cells. 
5.1. A Flexible and Expandable Custom R Routine Designed for 
Automated Microarray Analysis, From QC Assessment to Functional 
Analysis 
 
We have implemented a streamlined R-routine that contains multiple functions to 
analyze our dataset from the beginning to end, i.e., preprocessing, quality control, 
differential expression, functional assessment, and visualization. The programs were 
written in modules allowing for addition of new modules of existing and customized R 
routines from BioConductor and/or related resources for Affymetrix multi group one-
factor analyses. Future perspectives include adding other functionalities in R 
environment.  
BioConductor packages for statistical analysis of microarray data have already been 
present for more than five years, and R-based programs are frequently used for 
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developing custom routines. However, R packages for functional annotation and 
analysis of microarray data with visual support started to flourish at late 2009 and early 
2010. Such existing packages provided benefits in designing and writing our R- routine. 
Our R-routine, although implementing similar but necessary steps many other online and 
standalone programs make use of in R language, it is unique because it performs all the 
intended analysis steps in a streamline manner, including functional analysis. 
Accordingly, we provide a tool which combines the necessary steps of a microarray 
analysis from beginning to the end, in R environment. Second, the specified R-routine 
has been designed to contain modules thus is highly flexible, customizable and easily 
expandable. 
5.2. Chronic Nicotine and Levamisole Treatment Affect SW620 Colon 
Cancer Cells Similarly 
 
Here in this study we show that the chronic nicotine and levamisole treatments induce 
similar responses in the SW620 cells. Over 1200 probes were found to be differentially 
expressed in the same direction with both treatments; this is striking and highly 
significant.  It is understandable that compounds binding to similar groups of receptors 
could have similar overall effects, since both levamisole and nicotine are agonists of 
acetylcholine receptors. However, it is still interesting because L-type and N-type 
AChRs are known to have diverged and no cross binding is known to occur at least in 
nematodes (Boulin et al., 2008). Unlike the case in nematodes, there is not any 
levamisole-sensitive subtype of AChRs known in mammals however it has been 
previously shown that levamisole is a weak agonist of nAChRs; and the difference is a 
matter of affinity. 
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Our findings demonstrated that when treated chronically, levamisole and nicotine might 
converge in the intracellular downstream effectors of cholinergic signaling, indicated by 
the very similar sets of genes, molecular and cellular processes being affected by these 
two compounds in the same direction. On the other hand, levamisole was thought to be 
selective for the helminths discriminating it from the host‟s receptors (Rayes et al., 
2004). In the light of our findings, there may not be such a selection but the timing and 
dosing might not be high enough to raise adverse effects on the host. Our findings 
suggest that treatment of 1 μM dosage chronically (for 7 days in our study) has 
considerable effect on the transcriptional profile of SW620 colon cancer cells and this 
effect is parallel to that obtained by nicotine when given in the same dosage and timing, 
1 μM for seven days. Levamisole have been used as an adjuvant at high doses at which 
levamisole‟s cytotoxic effects might over dominate (Dahl et al., 2009). Our study was 
performed at 1uM nicotine or levamisole, mimicking the systemic blood level of 
nicotine in smokers (Russell et al., 1980). At this dose, the effects of nicotine and 
levamisole is similar; but might not be compared to the high doses used in colorectal 
cancer treatment.   
 
In the chronic nicotine treatment, about 60% of the genes related to steroid biosynthesis 
were up-regulated along with a considerable portion of fatty acid biosynthesis, fatty acid 
metabolism and unsaturated fatty acid biosynthesis as well (Table 9) including pivotal 
enzymes of fatty acid and cholesterol synthesis, Acetyl-CoA Carboxylase (ACACA) and 
3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR). Based on these 
findings, it can be said that nicotine might have a considerable effect on general lipid 
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and steroid metabolism, at least at the cellular level. there was one very recent study 
implicating a role for nicotine in increased released of corticosteroids in nicotine self-
administration (Yu and Sharp, 2010). Although there had been studies demonstrating a 
correlation between nicotine and serum cholesterol levels (Altschul et al., 1955; 
Ashakumary and Vijayammal, 1997; Wenzel and Beckloff, 1958), there is not any 
previous study established to our knowledge demonstrating a directly nicotine-induced 
increase in gene expression of steroid and cholesterol biosynthesis genes at the cellular 
level.  
By no means less important, levamisole also has similar effects on lipid and steroid 
metabolisms. This finding is in line with the levamisole usage in steroid sensitive 
nephrotic syndrome, and explains how it might be possible to reduce steroids in 
treatment when levamisole was added (Davin and Merkus, 2005; Tanphaichitr et al., 
1980). Therefore, our findings seem to shed light, at least at the cellular level, to the 
steroid sparing effect of levamisole in treatment of nephrotic syndrome. 
5.3. Chronic nicotine and levamisole treatments increase aminoacid 
degradation 
 
Interestingly, we found out degradation metabolisms of many aminoacids were up-
regulated in response to chronic nicotine and levamisole treatment. These aminoacid 
metabolisms included valine, leucine and isoleucine degradation (~21% up-regulated), 
lysine degradation (~13% up-regulated), arginin and proline metabolism (~10% up-
regulated), beta-alanin metabolism (~10% up-regulated) histidine metabolism (~7% up-
regulated). Interestingly the most effected aminoacid metabolism was the degradation of 
valine, leucine and isoleucin. These three aminoacids are metabolized up until pyruvate, 
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an intermediary metabolite for cholesterol and lipid synthesis. Such two-sided impact 
might further accelerate steroid and lipid metabolisms. 
These findings are more interesting in the light of a recent study on growth inhibition of 
constitutively active EGFR expressing glioblastoma cells by inhibiton of lipid 
metabolism (Guo et al., 2009). In that study, by activating AMPK, a metabolic 
checkpoint downstream of the LKB1 tumor suppressor and inhibitor of mTORC1 
(Carracedo et al., 2008; Guo et al., 2007; Inoki et al., 2003), they show the suppression 
of ACACA and HMGCR to inhibit the tumor growth (Guo et al., 2009). Although, 
SW620 colon cancer cells are EGFR negative, lipid and steroid metabolism might still 
be important for membrane biosynthesis and this effect may be important in nicotine‟s 
proliferative activity much. 
5.4. Anti-apoptotic or proleferation inducing genes are down-regulated in 
chronic nicotine and levamisole exposure 
 
Confirmatory real-time experiments verified the decrease in anti-apoptotic gene XIAP 
with chronic treatment of nicotine or levamisole. Previously, nicotine, at 1 μM 
concentration, reported to inhibit apoptosis by up-regulating XIAP and survivin 
(Dasgupta et al., 2006). XIAP up-regulation was also confirmed by our group, recently, 
in 1 μM 48h treatment under SW620 cells under a serum starvation regime while it was 
not affected under normal growth conditions (Kaya, 2009). In our study we found both 
by analysis of microarray data and confirmed with qPCR that XIAP was downregulated 
with chronic exposure. Nicotine and levamisole, at 1 μM concentrations, lead to 
comparable decreases, yet consistent chronic exposure to 10 μM levamisole lead to a 
greater amount of reduction in XIAP expression. It is understandable that the effects of 
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nicotine on XIAP could differ by serum condition during the exposure to nicotine in a 
time dependent manner. It seems that unlike in the acute treatments, nicotine may not 
have an anti-apoptotic activity under the chronic treatment, however other genes 
involved in apoptosis should also be analyzed to summarize the effects of 
nicotine/levamisole effect on apoptosis in future studies. Since the change in XIAP 
levels are affected by serum levels as well as time of exposure to nicotine, the length of 
treatment periods should be carefully selected when these two compounds are studied. 
Previous studies have applied treatment regimes up to 14 days or longer (Konu et al., 
2004). Our findings should be repeated with additional samples at day 15 to conclude 
that the XIAP expression is time- and dose-dependent.  
The situation for FOSL2, a transcription factor of AP-1 (Eferl et al., 2008), has been very 
similar to those seen for XIAP. With AP-1 interaction FOSL2 was implicated in 
processes like proliferation, transformation, and differentiation (Bamberger et al., 2001; 
Milde-Langosch et al., 2008; Nakayama et al., 2008). FOSL2 expression, was found to 
be up-regulated also in previous study of our group, for 48h treatment under serum 
starvation conditons (Kaya, 2009). In our study FOSL2 expression was reduced. The 
differences between acute and chronic treatments might be differential; cell type might 
also be effective. Nevertheless, the differential response both between different growth 
conditons and between different time points is interesting. This type of flipping 
differential response was also seen for GULP1 and MAP1B genes. These findings higly 
indicate the wording for “long term” and “chronic” should be delicately used for 
nicotine treatment. The initial changes seen at day 7 might neuralize or might be 
reverted when nicotine was used for long term, i.e.> 15 days. Indeed, in the addiction 
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literature most experiments are performed at 14 days of exposure to nicotine at which 
the animals develop addiction to the drug (Konu et al., 2001). A similar time course 
might be appropriate for cancer cells and warrants further study. 
Taken together these data suggest that nicotine may have different affects at the acute 
and chronic levels. The genes nicotine modulate under different conditions are rather 
similar; however, the direction and magnitude of changes might differ depending on the 
time and dose of exposures. Future studies should focus on deciphering these time and 
dose dependent effects on genes involved in cell proliferative and apoptotic pathways to 
assess the impact of smoking in cancer progression and use of levamisole in treatment of 
cancers. The nicotine‟s effects might also be driven by the microenvironment the cells 
are found in. Therefore, conditions such as hypoxic stress, amino acid starvation, and 
oxidative stress emerge as possible avenues to explore for understaing how nicotine‟s 
role in proliferation and apoptosis change.
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6. FUTURE PERSPECTIVES 
 
In this study we surveyed the effect of nicotine and levamisole on SW620 colon cancer 
cell line. To analyze the effect of nicotine and levamisole on gene expression we 
performed a microarray study with SW620 cells treated with either 1 μM nicotine or 1 
μM levamisole for 7 days. For analysis of data, we designed and implemented a custom 
R-routine which makes extensive use of R-BioConductor Project. 
This study implicates that nicotine and levamisole might have strong effect on steroid 
biosynthetic, cholesterol biosynthetic and aminoacid degradation metabolisms among 
other pathways not focused in this thesis. Confirmatory real-time PCR experiments of 
genes involved in steroid, cholesterol biosynthesis and valine, leucine, degradation 
metabolisms should be performed. Future studies should also assess nicotine‟s 
contribution in dysregulation of other metabolic and signaling pathways using 
confirmatory qRTPCR studies. 
Our data suggest that nicotine‟s time dependent effects on genes involved in cell 
proliferation and apoptosis should be further assessed with replicated experiments 
performed at day 15 or later. Chronic affects of nicotine might not be apparent before 
within two weeks.  To get clearer picture of chronic nicotine treatment and its effect on 
apoptosis and proliferation, apoptosis rate and viability assays should be performed 
along with expression analysis of a number of pro- or anti-apoptotic genes. Cell cycle 
analyses also would be useful to comprehend the effect of nicotine and levamisole on 
cell division which provide information about the silence of the cells in terms of both 
proliferation and apoptosis.  
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Our customized R-routine provides useful means for streamline automated analysis of 
microarray data from quality control assessments to functional annotation and analysis. 
First and the foremost the routine lacks an effective interface which could make it easier 
to use for users  inexperienced in R programming language and environment. Second, 
the routine could be developed to include properties to perform array analyses from 
other species (e.g. zebrafish, mouse, rat) and include arrays produced other than 
Affymetrix Inc. 
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Table 11: Full KEGGscriıpt results. 
GROUPS Levamisole- Control Nicotine-Control Nicotine-Levamisole 
PATHWAY NAME DOWN 
% 
UP % DOWN 
% 
UP % DOWN 
% 
UP % 
Steroid biosynthesis - 47.06 - 58.82 - 5.88 
Terpenoid backbone biosynthesis - 26.67 - 26.67 - - 
Limonene and pinene degradation - 25.00 - 25.00 - - 
Lysine biosynthesis - - - 25.00 - - 
Propanoate metabolism 3.03 24.24 - 24.24 - - 
Valine, leucine and isoleucine 
degradation 
- 22.73 - 20.45 - 2.27 
Pentose phosphate pathway - 14.81 - 18.52 - - 
Glycerolipid metabolism 4.08 14.29 4.08 18.37 - - 
Glutathione metabolism - 1- - 18.00 - - 
Pyruvate metabolism 2.50 15.00 - 17.50 - - 
Fatty acid biosynthesis - 16.67 - 16.67 - - 
Citrate cycle (TCA cycle) - 9.68 - 16.13 - - 
Fatty acid metabolism - 16.67 - 14.29 - - 
Ubiquinone and other terpenoid-quinone 
biosynthesis 
- 14.29 - 14.29 - - 
Lysine degradation 2.17 10.87 2.17 13.04 - - 
Nicotinate and nicotinamide metabolism 4.17 8.33 4.17 12.50 4.17 - 
Tryptophan metabolism 2.50 1- 2.50 12.50 - - 
Thiamine metabolism - 12.50 12.50 12.50 - - 
Fatty acid elongation in mitochondria - - - 12.50 - - 
Galactose metabolism 3.85 7.69 3.85 11.54 3.85 - 
Butanoate metabolism - 14.29 - 11.43 - - 
Synthesis and degradation of ketone 
bodies 
- 11.11 - 11.11 - - 
Glycolysis / Gluconeogenesis 1.56 10.94 - 10.94 - - 
Biosynthesis of unsaturated fatty acids 4.76 14.29 - 9.52 - - 
Arginine and proline metabolism 1.85 9.26 3.70 9.26 - - 
beta-Alanine metabolism 4.55 22.73 4.55 9.09 - - 
Valine, leucine and isoleucine 
biosynthesis 
9.09 9.09 - 9.09 - - 
Glycerophospholipid metabolism 1.27 7.59 2.53 8.86 - - 
Fructose and mannose metabolism - 8.82 - 8.82 - - 
Inositol phosphate metabolism 5.26 5.26 8.77 8.77 - 1.75 
Nitrogen metabolism - 8.70 4.35 8.70 - - 
Ether lipid metabolism - 8.57 2.86 8.57 - - 
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Metabolic pathways 1.96 7.03 2.67 8.19 0.18 0.53 
Ascorbate and aldarate metabolism 4.00 8.00 4.00 8.00 - - 
Phosphatidylinositol signaling system 5.13 6.41 7.69 7.69 - 2.56 
Sulfur metabolism - - - 7.69 - - 
Steroid hormone biosynthesis 3.64 - 3.64 7.27 - - 
Pyrimidine metabolism 3.06 5.10 2.04 7.14 - - 
Histidine metabolism - 10.34 - 6.90 - - 
Riboflavin metabolism 6.25 6.25 - 6.25 6.25 - 
Primary bile acid biosynthesis 6.25 6.25 6.25 6.25 - - 
Pantothenate and CoA biosynthesis - 6.25 - 6.25 6.25 - 
Glyoxylate and dicarboxylate 
metabolism 
- 6.25 - 6.25 - - 
Other glycan degradation - - - 6.25 - - 
Cell cycle 3.48 5.22 1.74 6.09 0.87 2.61 
One carbon pool by folate 5.88 17.65 - 5.88 - 5.88 
p53 signaling pathway 12.86 8.57 7.14 5.71 - 4.29 
Metabolism of xenobiotics by 
cytochrome P450 
2.86 2.86 2.86 5.71 - - 
Drug metabolism - cytochrome P450 - 2.78 - 5.56 - - 
Pancreatic cancer 1.37 4.11 2.74 5.48 - 2.74 
Wnt signaling pathway 8.11 4.05 4.05 5.41 0.68 2.70 
Tyrosine metabolism 2.44 2.44 2.44 4.88 - - 
Colorectal cancer 4.76 3.57 3.57 4.76 1.19 4.76 
Apoptosis 5.88 4.71 1.18 4.71 - 5.88 
ErbB signaling pathway 1.15 5.75 4.60 4.60 1.15 3.45 
Glycosaminoglycan biosynthesis - 
chondroitin sulfate 
9.09 4.55 13.64 4.55 - - 
Oxidative phosphorylation - 2.99 0.75 4.48 - 0.75 
Glycosylphosphatidylinositol(GPI)-
anchor biosynthesis 
- 4.00 4.00 4.00 - - 
Purine metabolism 3.14 2.52 1.89 3.77 0.63 0.63 
Pentose and glucuronate 
interconversions 
3.57 7.14 3.57 3.57 - - 
Glycosphingolipid biosynthesis - lacto 
and neolacto series 
3.57 3.57 3.57 3.57 - - 
Arachidonic acid metabolism - 1.72 - 3.45 - - 
O-Glycan biosynthesis - 1- 3.33 3.33 - - 
Glycine, serine and threonine 
metabolism 
3.23 - 3.23 3.23 - - 
Alanine, aspartate and glutamate 
metabolism 
6.25 3.13 6.25 3.13 - - 
Retinol metabolism - 1.56 1.56 3.13 - - 
VEGF signaling pathway 4.11 4.11 2.74 2.74 - 2.74 
MAPK signaling pathway 3.40 4.15 3.02 2.64 0.75 1.13 
Sphingolipid metabolism - 2.50 2.50 2.50 - - 
Aminoacyl-tRNA biosynthesis 4.88 - 2.44 2.44 - 2.44 
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Porphyrin and chlorophyll metabolism - 2.38 2.38 2.38 - - 
Amino sugar and nucleotide sugar 
metabolism 
6.82 2.27 6.82 2.27 - 2.27 
N-Glycan biosynthesis 4.17 2.08 6.25 2.08 - - 
Drug metabolism - other enzymes 3.92 - 1.96 1.96 - - 
Starch and sucrose metabolism 1.92 - 1.92 1.92 3.85 - 
Jak-STAT signaling pathway 3.87 1.94 4.52 0.65 - 1.29 
Glycosphingolipid biosynthesis - ganglio 
series 
6.67 - 13.33 - - - 
TGF-beta signaling pathway 3.37 3.37 2.25 - 1.12 - 
Taurine and hypotaurine metabolism - 1- - - - - 
Glycosaminoglycan degradation 4.76 - 4.76 - - - 
Cysteine and methionine metabolism 2.94 2.94 - - - - 
Phenylalanine metabolism 5.88 - 5.88 - - - 
Selenoamino acid metabolism - 3.85 - - - - 
Glycosaminoglycan biosynthesis - 
keratan sulfate 
6.67 - 6.67 - - - 
Folate biosynthesis - 9.09 - - - - 
D-Glutamine and D-glutamate 
metabolism 
- - 25.00 - - - 
Glycosaminoglycan biosynthesis - 
heparan sulfate 
- - 3.85 - - - 
Vitamin B6 metabolism - - 16.67 - - - 
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Table 12: Full GO_HyperG results. 
GOBPID Pvalue OddsRatio ExpCount Count Size Term 
GO:0006695 0.000564325 4.039671683 3.652889457 11 33 cholesterol biosynthetic process 
GO:0019637 0.000581941 1.928817584 21.36386864 37 193 organophosphate metabolic process 
GO:0044238 0.000617484 1.199125313 794.3374164 853 7176 primary metabolic process 
GO:0044282 0.000669365 1.843316923 24.57398362 41 222 small molecule catabolic process 
GO:0061035 0.000931469 8.06271302 1.328323439 6 12 regulation of cartilage development 
GO:0045007 0.001353882 Inf 0.33208086 3 3 depurination 
GO:0006006 0.00175041 1.931821932 17.2682047 30 156 glucose metabolic process 
GO:0006694 0.00176201 2.199981282 11.40144285 22 103 steroid biosynthetic process 
GO:0051346 0.001879224 3.127243823 4.759825656 12 43 negative regulation of hydrolase activity 
GO:0046395 0.002250175 2.068631338 13.06184715 24 118 carboxylic acid catabolic process 
GO:0048519 0.002282815 1.250419397 196.9239498 233 1779 negative regulation of biological process 
GO:0055114 0.002517021 1.419127258 66.63755918 89 602 oxidation reduction 
GO:0006986 0.002591974 2.580115577 6.863004434 15 62 response to unfolded protein 
GO:0040007 0.002662201 1.478176221 51.25114601 71 463 growth 
GO:0005996 0.00296543 1.703153822 24.90606448 39 225 monosaccharide metabolic process 
GO:0051270 0.00344003 1.757315546 21.1424814 34 191 regulation of cellular component movement 
GO:0006066 0.003585162 1.706666774 23.56749732 37 215 alcohol metabolic process 
GO:0007050 0.003702983 2.047212782 12.06560457 22 109 cell cycle arrest 
GO:0032332 0.003971791 10.73837077 0.774855339 4 7 positive regulation of chondrocyte 
differentiation 
GO:0042127 0.004440273 1.347353547 83.02021492 106 750 regulation of cell proliferation 
GO:0008361 0.004582991 1.609780542 28.78034117 43 260 regulation of cell size 
GO:0000122 0.004709697 1.616759566 28.00548583 42 253 negative regulation of transcription from 
RNA polymerase II promoter 
GO:0031324 0.005284238 1.349457597 78.14969565 100 706 negative regulation of cellular metabolic 
process 
GO:0007017 0.005814032 1.593683262 28.33756669 42 256 microtubule-based process 
GO:0006633 0.005848727 2.076657125 10.29450665 19 93 fatty acid biosynthetic process 
GO:0043603 0.006022723 2.499934768 6.088149094 13 55 cellular amide metabolic process 
GO:0008654 0.006261784 3.170616966 3.528700906 9 32 phospholipid biosynthetic process 
GO:0006613 0.006700866 5.754671078 1.328323439 5 12 cotranslational protein targeting to 
membrane 
GO:0050650 0.006700866 5.754671078 1.328323439 5 12 chondroitin sulfate proteoglycan 
biosynthetic process 
GO:0048514 0.006872052 1.58480979 27.78409859 41 251 blood vessel morphogenesis 
GO:0016481 0.006893935 1.424735097 49.81212895 67 450 negative regulation of transcription 
GO:0045944 0.007028283 1.491020518 37.85721801 53 342 positive regulation of transcription from 
RNA polymerase II promoter 
GO:0001709 0.007131938 3.395724807 2.988727737 8 27 cell fate determination 
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GO:0043436 0.00742927 1.370596693 63.09536334 82 570 oxoacid metabolic process 
GO:0016043 0.007495528 1.182832729 284.3719095 320 2569 cellular component organization 
GO:0001892 0.007639967 3.762301046 2.435259638 7 22 embryonic placenta development 
GO:0048255 0.007665514 4.395984384 1.881791538 6 17 mRNA stabilization 
GO:0048522 0.007902306 1.288618485 101.8767255 125 932 positive regulation of cellular process 
GO:0045839 0.009908588 5.034911444 1.439017059 5 13 negative regulation of mitosis 
GO:0042364 0.009952832 3.526858799 2.545953258 7 23 water-soluble vitamin biosynthetic process 
GO:0002062 0.01033003 4.039302802 1.988120301 6 18 chondrocyte differentiation 
GO:0009108 0.010501713 2.216963002 7.195085293 14 65 coenzyme biosynthetic process 
GO:0051254 0.010623261 1.394943649 49.92282257 66 451 positive regulation of RNA metabolic 
process 
GO:0010985 0.011394012 12.07346939 0.553468099 3 5 negative regulation of lipoprotein particle 
clearance 
GO:0034382 0.011394012 12.07346939 0.553468099 3 5 chylomicron remnant clearance 
GO:0042026 0.011394012 12.07346939 0.553468099 3 5 protein refolding 
GO:0070071 0.011394012 12.07346939 0.553468099 3 5 proton-transporting two-sector ATPase 
complex assembly 
GO:0009890 0.011411925 1.3467574 62.43120162 80 564 negative regulation of biosynthetic process 
GO:0009083 0.011869143 6.450170416 0.995114251 4 9 branched chain family amino acid catabolic 
process 
GO:0051172 0.011897624 1.363129096 56.34305253 73 509 negative regulation of nitrogen compound 
metabolic process 
GO:0010941 0.011974357 1.284571514 90.43668746 111 817 regulation of cell death 
GO:0000320 0.012245679 Inf 0.22138724 2 2 re-entry into mitotic cell cycle 
GO:0001808 0.012245679 Inf 0.22138724 2 2 negative regulation of type IV 
hypersensitivity 
GO:0002086 0.012245679 Inf 0.22138724 2 2 diaphragm contraction 
GO:0002865 0.012245679 Inf 0.22138724 2 2 negative regulation of acute inflammatory 
response to antigenic stimulus 
GO:0006436 0.012245679 Inf 0.22138724 2 2 tryptophanyl-tRNA aminoacylation 
GO:0009162 0.012245679 Inf 0.22138724 2 2 deoxyribonucleoside monophosphate 
metabolic process 
GO:0009211 0.012245679 Inf 0.22138724 2 2 pyrimidine deoxyribonucleoside 
triphosphate metabolic process 
GO:0032753 0.012245679 Inf 0.22138724 2 2 positive regulation of interleukin-4 
production 
GO:0033615 0.012245679 Inf 0.22138724 2 2 mitochondrial proton-transporting ATP 
synthase complex assembly 
GO:0034638 0.012245679 Inf 0.22138724 2 2 phosphatidylcholine catabolic process 
GO:0043117 0.012245679 Inf 0.22138724 2 2 positive regulation of vascular permeability 
GO:0045743 0.012245679 Inf 0.22138724 2 2 positive regulation of fibroblast growth 
factor receptor signaling pathway 
GO:0050882 0.012245679 Inf 0.22138724 2 2 voluntary musculoskeletal movement 
GO:0051365 0.012245679 Inf 0.22138724 2 2 cellular response to potassium ion starvation 
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GO:0060696 0.012245679 Inf 0.22138724 2 2 regulation of phospholipid catabolic process 
GO:0090042 0.012245679 Inf 0.22138724 2 2 tubulin deacetylation 
GO:0007040 0.012736673 3.319115641 2.656646878 7 24 lysosome organization 
GO:0010551 0.012792657 1.896063647 11.06936199 19 100 regulation of gene-specific transcription 
from RNA polymerase II promoter 
GO:0009966 0.012986139 1.270704802 97.07830465 118 877 regulation of signal transduction 
GO:0045017 0.01381122 4.494463536 1.543806647 5 14 glycerolipid biosynthetic process 
GO:0001569 0.013855587 3.719049866 2.103178778 6 19 patterning of blood vessels 
GO:0046460 0.01403032 4.475098395 1.549710679 5 14 neutral lipid biosynthetic process 
GO:0006638 0.014189586 2.695453507 3.975626269 9 36 neutral lipid metabolic process 
GO:0006662 0.014196153 2.69522504 3.975925369 9 36 glycerol ether metabolic process 
GO:0019362 0.014355365 2.520933014 4.649132036 10 42 pyridine nucleotide metabolic process 
GO:0031667 0.014411399 1.619404019 19.92485158 30 180 response to nutrient levels 
GO:0009101 0.0151723 1.64228474 18.3751409 28 166 glycoprotein biosynthetic process 
GO:0019320 0.015523882 2.093265301 7.527166153 14 68 hexose catabolic process 
GO:0006284 0.016038804 3.134455055 2.767340497 7 25 base-excision repair 
GO:0044264 0.016671005 2.141529214 6.863004434 13 62 cellular polysaccharide metabolic process 
GO:0009394 0.017980316 3.453111306 2.213872398 6 20 2'-deoxyribonucleotide metabolic process 
GO:0030968 0.017980316 3.453111306 2.213872398 6 20 endoplasmic reticulum unfolded protein 
response 
GO:0006098 0.018142932 5.367823916 1.106936199 4 10 pentose-phosphate shunt 
GO:0007094 0.018142932 5.367823916 1.106936199 4 10 mitotic cell cycle spindle assembly 
checkpoint 
GO:0001944 0.018926412 1.45505431 31.28129935 43 283 vasculature development 
GO:0042981 0.018996923 1.263540134 88.31052632 107 799 regulation of apoptosis 
GO:0007052 0.019163493 4.027247956 1.660404298 5 15 mitotic spindle organization 
GO:0046504 0.019163493 4.027247956 1.660404298 5 15 glycerol ether biosynthetic process 
GO:0001558 0.019891772 1.558665932 21.25317502 31 192 regulation of cell growth 
GO:0006493 0.019904143 2.969232426 2.878034117 7 26 protein amino acid O-linked glycosylation 
GO:0043487 0.019904143 2.969232426 2.878034117 7 26 regulation of RNA stability 
GO:0032787 0.020523893 1.415839234 35.75403923 48 323 monocarboxylic acid metabolic process 
GO:0016265 0.020527368 1.218333815 125.526565 147 1134 death 
GO:0051235 0.020720544 1.900117082 9.298264072 16 84 maintenance of location 
GO:0043068 0.020782179 1.357462455 47.15548208 61 426 positive regulation of programmed cell 
death 
GO:0007089 0.020922336 8.04829932 0.664161719 3 6 traversing start control point of mitotic cell 
cycle 
GO:0034379 0.020922336 8.04829932 0.664161719 3 6 very-low-density lipoprotein particle 
assembly 
GO:0046325 0.020922336 8.04829932 0.664161719 3 6 negative regulation of glucose import 
GO:0048193 0.021948448 1.693662827 14.05808973 22 127 Golgi vesicle transport 
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GO:0051186 0.022002926 1.556319633 20.5890133 30 186 cofactor metabolic process 
GO:0001763 0.022708027 1.922235286 8.634102352 15 78 morphogenesis of a branching structure 
GO:0009310 0.022708027 1.922235286 8.634102352 15 78 amine catabolic process 
GO:0006099 0.022872745 3.22263122 2.324566018 6 21 tricarboxylic acid cycle 
GO:0008633 0.022872745 3.22263122 2.324566018 6 21 activation of pro-apoptotic gene products 
GO:0071445 0.022872745 3.22263122 2.324566018 6 21 cellular response to protein stimulus 
GO:0009820 0.022972409 2.304267161 4.981212895 10 45 alkaloid metabolic process 
GO:0071216 0.024374415 2.82053206 2.988727737 7 27 cellular response to biotic stimulus 
GO:0032869 0.025260072 1.892039609 8.744795972 15 79 cellular response to insulin stimulus 
GO:0046627 0.025390202 3.66082487 1.771097918 5 16 negative regulation of insulin receptor 
signaling pathway 
GO:0030335 0.025449235 1.806372903 10.29450665 17 93 positive regulation of cell migration 
GO:0016051 0.025831105 1.661722177 14.27947697 22 129 carbohydrate biosynthetic process 
GO:0016053 0.026018048 1.571017045 18.3751409 27 166 organic acid biosynthetic process 
GO:0006641 0.028205529 3.031335616 2.427883168 6 22 triglyceride metabolic process 
GO:0044255 0.028339134 1.333356746 47.06397638 60 429 cellular lipid metabolic process 
GO:0044262 0.02838336 1.586802395 16.85830207 25 154 cellular carbohydrate metabolic process 
GO:0050879 0.028585037 3.020961145 2.435259638 6 22 multicellular organismal movement 
GO:0060070 0.028585037 3.020961145 2.435259638 6 22 Wnt receptor signaling pathway through 
beta-catenin 
GO:0008203 0.028607713 2.028275862 6.608407413 12 60 cholesterol metabolic process 
GO:0010876 0.028815549 1.540550338 19.37138348 28 175 lipid localization 
GO:0030178 0.029105987 2.480021003 3.763583077 8 34 negative regulation of Wnt receptor 
signaling pathway 
GO:0048870 0.029378738 1.337046258 45.38438416 58 410 cell motility 
GO:0046474 0.030403767 1.942415018 7.416472533 13 67 glycerophospholipid biosynthetic process 
GO:0009119 0.030479016 2.179342706 5.202600135 10 47 ribonucleoside metabolic process 
GO:0015980 0.030724272 1.590062112 16.16126851 24 146 energy derivation by oxidation of organic 
compounds 
GO:0044275 0.030930064 1.79394494 9.741038551 16 88 cellular carbohydrate catabolic process 
GO:0009891 0.031125489 1.260243047 72.61501465 88 656 positive regulation of biosynthetic process 
GO:0031325 0.031128383 1.228889341 93.75749605 111 847 positive regulation of cellular metabolic 
process 
GO:0042176 0.032178796 2.063134286 5.977455475 11 54 regulation of protein catabolic process 
GO:0001578 0.032775489 3.355472298 1.881791538 5 17 microtubule bundle formation 
GO:0006739 0.032775489 3.355472298 1.881791538 5 17 NADP metabolic process 
GO:0046503 0.032775489 3.355472298 1.881791538 5 17 glycerolipid catabolic process 
GO:0006882 0.033635244 6.035714286 0.774855339 3 7 cellular zinc ion homeostasis 
GO:0006978 0.033635244 6.035714286 0.774855339 3 7 DNA damage response, signal transduction 
by p53 class mediator resulting in 
transcription of p21 class mediator 
GO:0009103 0.033635244 6.035714286 0.774855339 3 7 lipopolysaccharide biosynthetic process 
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GO:0017085 0.033635244 6.035714286 0.774855339 3 7 response to insecticide 
GO:0030219 0.033635244 6.035714286 0.774855339 3 7 megakaryocyte differentiation 
GO:0031112 0.033635244 6.035714286 0.774855339 3 7 positive regulation of microtubule 
polymerization or depolymerization 
GO:0033032 0.033635244 6.035714286 0.774855339 3 7 regulation of myeloid cell apoptosis 
GO:0051006 0.033635244 6.035714286 0.774855339 3 7 positive regulation of lipoprotein lipase 
activity 
GO:0035108 0.033978947 1.769219921 9.851732171 16 89 limb morphogenesis 
GO:0006552 0.034029275 16.08837525 0.33208086 2 3 leucine catabolic process 
GO:0007549 0.034029275 16.08837525 0.33208086 2 3 dosage compensation 
GO:0008356 0.034029275 16.08837525 0.33208086 2 3 asymmetric cell division 
GO:0009221 0.034029275 16.08837525 0.33208086 2 3 pyrimidine deoxyribonucleotide 
biosynthetic process 
GO:0014012 0.034029275 16.08837525 0.33208086 2 3 axon regeneration in the peripheral nervous 
system 
GO:0015808 0.034029275 16.08837525 0.33208086 2 3 L-alanine transport 
GO:0015917 0.034029275 16.08837525 0.33208086 2 3 aminophospholipid transport 
GO:0032727 0.034029275 16.08837525 0.33208086 2 3 positive regulation of interferon-alpha 
production 
GO:0042149 0.034029275 16.08837525 0.33208086 2 3 cellular response to glucose starvation 
GO:0043517 0.034029275 16.08837525 0.33208086 2 3 positive regulation of DNA damage 
response, signal transduction by p53 class 
mediator 
GO:0051964 0.034029275 16.08837525 0.33208086 2 3 negative regulation of synaptogenesis 
GO:0051988 0.034029275 16.08837525 0.33208086 2 3 regulation of attachment of spindle 
microtubules to kinetochore 
GO:0070050 0.034029275 16.08837525 0.33208086 2 3 neuron homeostasis 
GO:0070272 0.034029275 16.08837525 0.33208086 2 3 proton-transporting ATP synthase complex 
biogenesis 
GO:0052547 0.034198223 1.806860758 9.076876832 15 82 regulation of peptidase activity 
GO:0006213 0.035161109 2.843016961 2.545953258 6 23 pyrimidine nucleoside metabolic process 
GO:0009954 0.035161109 2.843016961 2.545953258 6 23 proximal/distal pattern formation 
GO:0050680 0.035161109 2.843016961 2.545953258 6 23 negative regulation of epithelial cell 
proliferation 
GO:0006084 0.035276484 2.563685973 3.210114977 7 29 acetyl-CoA metabolic process 
GO:0006984 0.035433483 4.036910458 1.324904042 4 12 ER-nuclear signaling pathway 
GO:0019432 0.03573195 4.025187202 1.328323439 4 12 triglyceride biosynthetic process 
GO:0008104 0.036311138 1.205928573 107.3728113 125 970 protein localization 
GO:0007173 0.037429701 2.198397914 4.649132036 9 42 epidermal growth factor receptor signaling 
pathway 
GO:0035239 0.039019155 1.60018712 14.05808973 21 127 tube morphogenesis 
GO:0055086 0.039444074 1.316077036 44.38814158 56 401 nucleobase, nucleoside and nucleotide 
metabolic process 
GO:0001764 0.039567165 2.067231015 5.423987375 10 49 neuron migration 
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GO:0006720 0.039567165 2.067231015 5.423987375 10 49 isoprenoid metabolic process 
GO:0070887 0.039617233 1.370904686 32.87600511 43 297 cellular response to chemical stimulus 
GO:0044237 0.04033255 1.117182034 502.5485581 531 4814 cellular metabolic process 
GO:0045941 0.040709611 1.272308874 58.00345683 71 524 positive regulation of transcription 
GO:0000079 0.040882124 1.971105031 6.198842714 11 56 regulation of cyclin-dependent protein 
kinase activity 
GO:0051225 0.041366394 3.097097045 1.992485158 5 18 spindle assembly 
GO:0007224 0.041769828 2.452013761 3.320808597 7 30 smoothened signaling pathway 
GO:0042246 0.041769828 2.452013761 3.320808597 7 30 tissue regeneration 
GO:0006829 0.042635921 2.684844354 2.656646878 6 24 zinc ion transport 
GO:0009109 0.042635921 2.684844354 2.656646878 6 24 coenzyme catabolic process 
GO:0045669 0.042635921 2.684844354 2.656646878 6 24 positive regulation of osteoblast 
differentiation 
GO:0007049 0.044211846 1.201327434 100.7311941 117 910 cell cycle 
GO:0051253 0.045363134 1.323724618 39.40692868 50 356 negative regulation of RNA metabolic 
process 
GO:0042476 0.045792608 1.928091358 6.309536334 11 57 odontogenesis 
GO:0006766 0.045847849 1.764693283 8.634102352 14 78 vitamin metabolic process 
GO:0008624 0.04598303 1.632572686 11.84421733 18 107 induction of apoptosis by extracellular 
signals 
GO:0016578 0.047208999 3.577641631 1.439017059 4 13 histone deubiquitination 
GO:0019433 0.047208999 3.577641631 1.439017059 4 13 triglyceride catabolic process 
GO:0031577 0.047208999 3.577641631 1.439017059 4 13 spindle checkpoint 
GO:0043154 0.047208999 3.577641631 1.439017059 4 13 negative regulation of caspase activity 
GO:0043193 0.04838207 1.676741927 10.29450665 16 93 positive regulation of gene-specific 
transcription 
GO:0048736 0.04838207 1.676741927 10.29450665 16 93 appendage development 
GO:0010827 0.048990293 2.349647567 3.431502217 7 31 regulation of glucose transport 
GO:0051650 0.048990293 2.349647567 3.431502217 7 31 establishment of vesicle localization 
GO:0007010 0.049314479 1.272046647 52.24738859 64 472 cytoskeleton organization 
GO:0001945 0.049466161 4.828163265 0.885548959 3 8 lymph vessel development 
GO:0002262 0.049466161 4.828163265 0.885548959 3 8 myeloid cell homeostasis 
GO:0008354 0.049466161 4.828163265 0.885548959 3 8 germ cell migration 
GO:0009113 0.049466161 4.828163265 0.885548959 3 8 purine base biosynthetic process 
GO:0009263 0.049466161 4.828163265 0.885548959 3 8 deoxyribonucleotide biosynthetic process 
GO:0018065 0.049466161 4.828163265 0.885548959 3 8 protein-cofactor linkage 
GO:0030858 0.049466161 4.828163265 0.885548959 3 8 positive regulation of epithelial cell 
differentiation 
GO:0035313 0.049466161 4.828163265 0.885548959 3 8 wound healing, spreading of epidermal cells 
GO:0043094 0.049466161 4.828163265 0.885548959 3 8 cellular metabolic compound salvage 
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QualCont FUNCTION 
QualCont<-function (FilesPath,NormType,pdfile) 
{ 
#FilesPath: location of the .CEL files 
#NormType: string defining the type of normalization method; "rma", "gcrma" or 
#  "mas5" 
#pdfile: phenodata file created by user; tab delimited .txt file 
 
#rma and gcrma generates logged values of signal intensity while mas5 not.. 
#therefore log status of the signal intensity is set to 1 or 0. 
#This information is needed for log fold-change calculation in DEGidentifier 
#function... 
if(NormType=="mas5") LOG.STAT<-0 else LOG.STAT<-1 
assign("LOG.STAT", LOG.STAT, envir=.GlobalEnv) 
 
library(affy) 
library(affyPLM) 
 
#FilesPath given by the user is set as the 
#working directory. 
 
setwd(FilesPath) 
 
 
#phenodata file is read; 
#.CEL files are read with phenodata file... 
 
read.AnnotatedDataFrame(pdfile,header=TRUE,row.names=1,as.is=TRUE)->pd 
assign("pd",pd, envir=.GlobalEnv) 
rawAffyData <- ReadAffy(filenames=pData(pd)$FileName,phenoData=pd,verbose=TRUE) 
assign("rawAffyData",rawAffyData,envir=.GlobalEnv) 
groups<-levels(as.factor(pData(pd)[,2])) 
assign("groups", groups, envir=.GlobalEnv) 
ind=vector(mode="integer",length=length(pData(pd)[,2])) 
 
if (length(groups)<2) { 
cat ("There must be at least 2 groups defined") 
break 
} 
 
for (i in 1:length(groups)) { 
tempind=which(pData(pd)[,2]==groups[i]) 
ind[tempind]<-rep(i,length(tempind)) 
} 
 
assign("ind",ind, envir=.GlobalEnv) 
 
 
#normalization is performed... 
 
switch (NormType, 
rma=assign("normdata", rma(rawAffyData)), 
mas5=assign("normdata", mas5(rawAffyData)), 
gcrma=assign("normdata", gcrma(rawAffyData)) 
) 
 
if(exists("normdata")) { 
ndata<-exprs(normdata) 
 
#normalized data matrix and groups are saved into 
#Global environment for further and easier usage in 
#other functions... see DEGidentifier and Grapher... 
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assign("ndata",ndata, envir=.GlobalEnv) 
assign("groups",groups, envir=.GlobalEnv) 
} 
else 
{ 
paste("This Function does not know a normalization method 
called",NormType,"\n")->err1 
cat(err1) 
break 
} 
 
#normalized data is saved into working directory... 
write(ndata, file="ndata.xls", sep="\t") 
 
#.CEL file names are arranged for output file denomination... 
#last 4 characters are deleted (.CEL) 
colnames(ndata)->cfn 
cfn<-as.vector(sapply(cfn, function(x) substr(x,1,(nchar(x)-4)))) 
 
#chip images are generated... 
for (i in 1:ncol(ndata)){ 
jpeg(paste(cfn[i],".jpeg",sep=""),width=1080,height=840) 
image(rawAffyData[,i]) 
dev.off() 
} 
 
#Histograms of in-array signal intensity distribution 
#of raw data for each array are generated... 
for(i in 1:ncol(ndata)){ 
jpeg(file=paste(cfn[i],"HIST_raw.jpeg",sep=""),width=1080,height=840) 
hist(log2(intensity(rawAffyData[,i])),breaks = 100, col = 
"blue",main=paste("Histogram of raw", cfn[i]),xlab=cfn[i]) 
dev.off() 
} 
 
 
#Histograms of in-array signal intensity distribution 
#of normalized data for each array are generated... 
for(i in 1:ncol(ndata)){ 
jpeg(file=paste(cfn[i],"HIST_normalized.pjpeg",sep=""),width=1080,height=840) 
hist(ndata[,i],breaks = 100, col = "blue",main=paste("Histogram of normalized", 
cfn[i]),xlab=cfn[i]) 
dev.off() 
} 
 
#Boxplots of in-array signal intensity distribution 
#of raw data for each array are generated... 
jpeg(file="raw_BOXPLOT.jpeg",width=1080,height=840) 
boxplot(rawAffyData, col="red", main="Boxplot of Raw Data", xlab="Chip Names", 
ylab= 
"Raw Intensity Values") 
dev.off() 
 
 
#Boxplots of in-array signal intensity distribution 
#of normalized data for each array are generated... 
jpeg(file="normalized_BOXPLOT.jpeg",width=1080,height=840) 
boxplot(ndata, col="red", main="Boxplot of Normalized Data", xlab="Chip Names", 
ylab= "Normalized Intensity Values") 
dev.off() 
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#paired MA PLOTs of the raw data are generated...  
jpeg(file="MAPlots_raw.jpeg",width=1080,height=840) 
mva.pairs(pm(rawAffyData)) 
dev.off() 
 
#paired MA PLOTs of the normalized data are generated... 
pdf(file="MAPlots_norm.pdf",width=1080,height=840) 
mva.pairs(ndata) 
dev.off() 
 
#RNA quality control assessments.... 
jpeg(file="RNA_Degradation_Plot.jpeg",width=1080,height=840) 
RNA_degradation<-AffyRNAdeg(rawAffyData,log.it=TRUE) 
summary_RNADEG<-summaryAffyRNAdeg(RNA_degradation,signif.digits=3) 
write.table(summary_RNADEG, file="summaryRNADEG.xls", sep="\t") 
plotAffyRNAdeg(RNA_degradation, transform = "shift.scale", cols = 
rainbow(ncol(ndata))) 
dev.off() 
 
#RLE (Relative Log Expression) plot is generated... 
Pset<-fitPLM(rawAffyData) 
jpeg(file="RLE_BoxPlot.jpeg",width=1080,height=840) 
RLE(Pset,main="RLE for Raw Data") 
dev.off() 
 
} 
#End of the function....
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DEGidentifier FUNCTION 
 
DEGidentifier<-function(ndata,pdfile,lfc,method,adjust.method,p.value){ 
 
#ndata: normalized data matrix; exprs() funtion output... 
#pdfile: experiment descriptor (phenodata) file... 
#lfc:  log fold change treshold to be applied for filtering... 
#method: character string specify how probes and contrasts are to be 
#  combined in the multiple testing strategy.  Choices are 
#  ‘"separate"’, ‘"global"’, ‘"hierarchical"’, 
#  ‘"nestedF"’ or any partial string. 
#adjust.method: character string specifying p-value adjustment method. 
#   Possible values are ‘"none"’, ‘"BH"’, ‘"fdr"’ 
#   (equivalent to ‘"BH"’), ‘"BY"’ and ‘"holm"’. 
#p.value:  numeric value between 0 and 1 giving the desired pvalue 
#  treshold to be applied for the test... 
 
 
method <- match.arg(method, c("separate", "global", "hierarchical","nestedF")) 
adjust.method <- match.arg(adjust.method, c("none", "bonferroni","holm", "BH", 
"fdr", "BY")) 
 
 
library(limma) 
library(hgu133plus2.db) 
library(made4) 
#made4 package is dependent on the following packages: 
#ade4,gplots,gtools,gdata,caTools,bitops and scatterplot... 
#ensure all these packages are already installed before calling made4... 
 
 
#Generation of contrast matrix from phenodata file automatically... 
pd<-readTargets(pdfile,sep="") 
f<-paste(pd$Target,sep="") 
f<-factor(f) 
 
design<-model.matrix(~0+f) 
colnames(design)<-levels(f) 
 
ContrastTemplet<-vector() 
 
TempComb<-combn(colnames(design),2) 
for (i in 1:ncol(TempComb)){ 
ContrastTemplet[i]<-paste(TempComb[2,i],"-",TempComb[1,i],sep="") 
} 
ContrastTemplet[1]->cd 
assign("cd",cd,envir=.GlobalEnv) 
contrast.matrix<-makeContrasts(cd,levels=design) 
 
if (length(levels(f)>=3){ 
for (i in 2:length(ContrastTemplet)){ 
ContrastTemplet[i]->cd 
assign("cd",cd,envir=.GlobalEnv) 
Temp.contrast.matrix<-makeContrasts(cd,levels=design) 
contrast.matrix<-cbind(contrast.matrix,Temp.contrast.matrix) 
} 
} 
 
#contrast matrix is saved to global environment to enable user 
#to check whether it is correct... 
assign("contrast.matrix", contrast.matrix,envir=.GlobalEnv) 
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#fitting the data to a linear model and 
#emprical Bayes moderation.... 
fit<-lmFit(ndata,design) 
fit2<-contrasts.fit(fit,contrast.matrix) 
fit2<-eBayes(fit2) 
assign("fit",fit,envir=.GlobalEnv) 
assign("fit2", fit2, envir=.GlobalEnv) 
 
#Top 10 testing results for each comparison to give an idea... 
print("These are some of your top results...") 
for(i in 1:length(ContrastTemplet)){ 
print(ContrastTemplet[i]) 
print(topTable(fit2,coef=i,adjust="BH"),zero.print=".") 
} 
 
 
#Actual testing and determination of DEGs with parameters given by the user... 
results<-
decideTests(fit2,method=method,adjust.method=adjust.method,p.value=p.value,lfc=
lfc) 
 
#testing results are saved to Global environment to enable 
#user to check and for further and easier usage in other functions, 
#see KEGGscript and Grapher... 
assign("results",results,envir=.GlobalEnv) 
 
#Generation of Venn Diagram for the DEGs.... 
jpeg(file="VennDiagram.pdf",width=1080,height=840) 
vennDiagram(results) 
dev.off() 
 
#List of all significant probes is generated and saved to working directory...  
TempSignif<-vector() 
TempSignif<-which(results[,1]!=0) 
TempSignifProbes<-names(TempSignif) 
write.table(TempSignifProbes,file=paste(colnames(results)[1],"SignifDEGProbes.x
ls",sep=""),sep="\t") 
AllSignifProbes<-TempSignifProbes 
 
if (length(levels(f)>=3){ 
for(i in 2:length(colnames(results))){ 
TempSignif<-which(results[,i]!=0) 
TempSignifProbes<-names(TempSignif) 
write.table(TempSignifProbes,file=paste(colnames(results)[i],"SignifDEGProbes.x
ls",sep=""),sep="\t") 
AllSignifProbes<-union(AllSignifProbes,names(TempSignif)) 
} 
} 
 
write.table(AllSignifProbes,file="AllSignifDEGProbes.xls",sep="\t") 
assign("AllSignifProbes",AllSignifProbes,envir=.GlobalEnv) 
 
 
#Lists of significant up- and downregulated probes and gene symbols 
#for each comparison are generated and saved to working directory... 
UPs<-vector() 
for(i in 1:ncol(results)){ 
UPs<-which(results[,i]==1) 
UPsProbes<-names(UPs) 
UPsGenes<-unlist(mget(UPsProbes,hgu133plus2SYMBOL,ifnotfound=NA)) 
UPsGenes<-as.vector(UPsGenes) 
UPsGenes<-UPsGenes[!is.na(UPsGenes)] 
UPsGenes<-UPsGenes[!duplicated(UPsGenes)] 
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write.table(UPsProbes,file=paste(colnames(results)[i],"UPsProbes.xls",sep=""),s
ep="\t") 
write.table(UPsGenes,file=paste(colnames(results)[i],"UPsGenes.xls",sep=""),sep
="\t") 
} 
 
 
 
DOWNs<-vector() 
for (i in 1:ncol(results)){ 
DOWNs<-which(results[,i]==-1) 
DOWNsProbes<-names(DOWNs) 
DOWNsGenes<-unlist(mget(DOWNsProbes,hgu133plus2SYMBOL,ifnotfound=NA)) 
DOWNsGenes<-as.vector(DOWNsGenes) 
DOWNsGenes<-DOWNsGenes[!is.na(DOWNsGenes)] 
DOWNsGenes<-DOWNsGenes[!duplicated(DOWNsGenes)] 
write.table(DOWNsProbes,file=paste(colnames(results)[i],"DOWNsProbes.xls",sep="
"),sep="\t") 
write.table(DOWNsGenes,file=paste(colnames(results)[i],"DOWNsGenes.xls",sep="")
,sep="\t") 
} 
 
 
#normalized data matrix of significant probes,"ndata2", 
#is extracted from whole normalized data matrix, "ndata", and 
#saved into global environment for further usage (see heatmap generation below) 
#and saved into working directory... 
Selected<-charmatch(rownames(ndata),AllSignifProbes) 
Indxs<-which(Selected!="NA") 
 
ndata2<-ndata[Indxs,] 
 
assign("ndata2",ndata2,envir=.GlobalEnv) 
write.table(ndata2,file="ndata.Of.Signif.Probes.txt",sep="\t") 
 
 
#HEATMAP GENERATION 
jpeg(file="HeatMap.jpeg",width=1080,height=840) 
heatplot(ndata2) 
dev.off() 
 
 
 
#averages of multiple replicates are calculated for log fold-change 
calculation... 
tempData<-ndata2 
colnames(tempData)<-as.vector(f) 
index<-which(colnames(tempData)==levels(f)[1]) 
meanGroups<-rowMeans(tempData[,index[1]:index[length(index)]]) 
meanGroups<-as.data.frame(meanGroups) 
 
 
for (i in 2:length(levels(f))){ 
index<-which(colnames(tempData)==levels(f)[i]) 
TempMeanGroups<-rowMeans(tempData[,index[1]:index[length(index)]]) 
TempmeanGroups<-as.data.frame(TempMeanGroups) 
meanGroups<-cbind(meanGroups,TempMeanGroups) 
} 
colnames(meanGroups)<-levels(f) 
 
 
#Log fold-change values are generated and saved into global environment 
#for further and easier usage by other functions (see Grapher), 
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#and saved into working directory for possible further usage by user... 
fc<-matrix(0,nrow=nrow(meanGroups),ncol=ncol(combn(ncol(meanGroups),2))) 
rownames(fc)<-rownames(meanGroups) 
colnames(fc)<-vector(mode="list",length=ncol(meanGroups)) 
meanGroups<-as.matrix(meanGroups) 
 
TempNames<-vector() 
Tempfc<-matrix() 
p=1 
 
if(LOG.STAT==1){ 
for(i in 1:(ncol(meanGroups)-1)){ 
for(j in (i+1):ncol(meanGroups)){  
Tempfc<-meanGroups[,j]-meanGroups[,i] 
TempNames<-paste(colnames(meanGroups)[j],"-",colnames(meanGroups)[i],sep="") 
fc[,p]<-Tempfc 
colnames(fc)[p]<-TempNames 
p=p+1 
} 
} 
} 
 
else{ 
for(i in 1:(ncol(meanGroups)-1)){ 
for(j in (i+1):ncol(meanGroups)){  
Tempfc<-meanGroups[,j]/meanGroups[,i] 
TempNames<-paste(colnames(meanGroups)[j],"-",colnames(meanGroups)[i],sep="") 
fc[,p]<-Tempfc 
colnames(fc)[p]<-TempNames 
p=p+1 
} 
} 
} 
 
assign("fc",fc,envir=.GlobalEnv) 
write.table(fc,file="fc_all.xls", sep="\t") 
 
 
#Plots for fold-change correspondences between comparisons are generated 
#and saved into working directory... 
 
Pairs<-combn(colnames(fc),2) 
 
for(i in 1:ncol(Pairs)){ 
Corresp.Title=paste("FC Corresp.", Pairs[1,i], "vs", Pairs[2,i], sep=" ") 
jpeg(file=paste(Corresp.Title, ".jpeg", sep="")) 
plot(fc[,Pairs[1,i]],fc[,Pairs[2,i]], main=Corresp.Title, xlab=Pairs[1,i], 
ylab=Pairs[2,i]) 
dev.off() 
} 
 
} 
#End of the function...
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KEGGscript FUNCTION 
 
KEGGscript<-function(results){ 
 
require(hgu133plus2.db) 
require(KEGG.db) 
require(KEGGgraph) 
require(Rgraphviz) 
require(GeneAnswers) 
 
####KEGG Pathway Annotation###### 
 
kegg_Paths<-mget(AllSignifProbes,hgu133plus2PATH, ifnotfound=NA) 
listem<-t(as.data.frame(kegg_Paths[1]))[1,] 
listem<-as.vector(listem) 
for(i in 2:length(kegg_Paths)){ 
listem<-union(listem,t(as.data.frame(kegg_Paths[i]))[1,]) 
} 
 
listem<-listem[which(listem!="NA")] 
assign("KEGGids",listem,envir=.GlobalEnv) 
write.table(listem, file="KEGGids.txt",sep="\t") 
########################################################## 
########################################################## 
 
#download the KGML files... 
destdir<-system.file("extdata",package="KEGGgraph",lib.loc=NULL) 
 
#for(i in 1:length(KEGGids)){ 
#retrieveKGML(KEGGids[i],organism="hsa",destfile=paste(destdir,"\\hsa",KEGGids[
i],".xml",sep=""),method="internal",quiet=TRUE) 
#} 
 
#read KGML files in and parse them as graph objects. 
FileList<-list() 
 for (i in 1:length(KEGGids)){ 
  FileList[i]<-
system.file(paste("extdata/hsa",KEGGids[i],".xml",sep=""),package="KEGGgraph") 
 } 
FileList<-FileList[is.na(charmatch(FileList,""))] 
FileList<-unlist(FileList) 
 
###KEGG ANNOTATION OF UP- AND DOWNREGULATED GENES IN EACH GROUP 
EntrezIDMaP <- hgu133plus2ENTREZID 
 for(i in 1:ncol(results)){ 
  write(paste(colnames(results)[i],"KEGG PATHWAY 
RESULTS...",sep="\n"),file=paste(colnames(results)[i],"KEGG_RESULTS.txt",sep=""
),    ncolumns=if(is.character(paste(colnames(results)[i],"KEGG 
PATHWAY RESULTS...",sep="\n"))) 1 else 5,append=FALSE) 
  
  RESTAB<-matrix(0,ncol=2,nrow=length(FileList)) 
  colnames(RESTAB)<-c("UP Percentage","DOWN Percentage") 
  rownames(RESTAB)<-vector(mode="list",length=length(FileList)) 
 
 
  for(j in 1:length(FileList)){ 
   KEGG_PATH<-parseKGML(FileList[j]) 
   KEGG_GRAPH<-KEGGpathway2Graph(KEGG_PATH,expandGenes=TRUE) 
 
 
   UPs<-vector() 
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   UPs<-which(results[,i]==1) 
   UPsENTREZ<-unlist(as.list(EntrezIDMaP[names(UPs)])) 
   UPsENTREZ<-as.vector(UPsENTREZ) 
   UPsENTREZ<-UPsENTREZ[!is.na(UPsENTREZ)] 
   UPsENTREZ<-UPsENTREZ[!duplicated(UPsENTREZ)] 
   UPsKEGGID<-translateGeneID2KEGGID(UPsENTREZ) 
 
   DOWNs<-vector() 
   
   DOWNs<-which(results[,i]==-1) 
   DOWNsENTREZ<-unlist(as.list(EntrezIDMaP[names(DOWNs)])) 
   DOWNsENTREZ<-as.vector(DOWNsENTREZ) 
   DOWNsENTREZ<-DOWNsENTREZ[!is.na(DOWNsENTREZ)] 
   DOWNsENTREZ<-DOWNsENTREZ[!duplicated(DOWNsENTREZ)] 
   DOWNsKEGGID<-translateGeneID2KEGGID(DOWNsENTREZ) 
 
   
   isMappedUP<-nodes(KEGG_GRAPH)%in% UPsKEGGID 
   if(mean(isMappedUP)==0){ 
   declarUP<-sprintf("No genes are upregulated...") 
   } 
   else{ 
   declarUP<-sprintf("%2.2f%% of genes are 
upregulated...",mean(isMappedUP)*100) 
   declarUP<-
paste("*************************","*************************",KEGG_PATH@pathway
Info@title, declarUP, sep="\n") 
   declarUP<-paste(declarUP,"GENES ARE:",sep="\n") 
   
   GENSYMBOLUP<-
unlist(mget(translateKEGGID2GeneID(nodes(KEGG_GRAPH)[isMappedUP==TRUE]), 
org.Hs.egSYMBOL, ifnotfound=NA)) 
   
  
 write(declarUP,file=paste(colnames(results)[i],"KEGG_RESULTS.txt",sep=""
), ncolumns=if(is.character(declarUP)) 1 else 5, append=TRUE) 
  
 write(GENSYMBOLUP,file=paste(colnames(results)[i],"KEGG_RESULTS.txt",sep
=""), ncolumns=if(is.character(GENSYMBOLUP)) 1 else 5, append=TRUE) 
   } 
 
   isMappedDOWN<-nodes(KEGG_GRAPH)%in% DOWNsKEGGID 
   if(mean(isMappedDOWN)==0){ 
   declarDOWN<-sprintf("No genes are downregulated...") 
   } 
   else{ 
   declarDOWN<-sprintf("%2.2f%% of genes are 
downregulated...",mean(isMappedDOWN)*100) 
   declarDOWN<-
paste("*************************","*************************", 
KEGG_PATH@pathwayInfo@title, declarDOWN, sep="\n") 
   declarDOWN<-paste(declarDOWN,"GENES ARE:",sep="\n") 
   
   GENSYMBOLDOWN<-
unlist(mget(translateKEGGID2GeneID(nodes(KEGG_GRAPH)[isMappedDOWN==TRUE]), 
org.Hs.egSYMBOL, ifnotfound=NA)) 
   } 
  
 write(declarDOWN,file=paste(colnames(results)[i],"KEGG_RESULTS.txt",sep=
""), ncolumns=if(is.character(declarDOWN)) 1 else 5, append=TRUE) 
  
 write(GENSYMBOLDOWN,file=paste(colnames(results)[i],"KEGG_RESULTS.txt",s
ep=""), ncolumns=if(is.character(GENSYMBOLDOWN)) 1 else 5, append=TRUE) 
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   rownames(RESTAB)[j]<-KEGG_PATH@pathwayInfo@title 
   RESTAB[j,1]<-mean(isMappedUP)*100 
   RESTAB[j,2]<-mean(isMappedDOWN)*100 
   } 
   
 
 write.table(RESTAB,file=paste("KEGG_TABLE",colnames(results)[i],".xls",s
ep=""),sep="\t") 
 
 
x<-
geneAnswersBuilder(UPsENTREZ,"org.Hs.eg.db",categoryType="GO.BP",testType="hype
rG",pvalueT=0.1,FDR.correction=TRUE,geneExpressionProfile=NULL) 
y<-
geneAnswersBuilder(UPsENTREZ,"org.Hs.eg.db",categoryType="KEGG",testType="hyper
G",pvalueT=0.1,FDR.correction=TRUE,geneExpressionProfile=NULL) 
z<-
geneAnswersBuilder(DOWNsENTREZ,"org.Hs.eg.db",categoryType="GO.BP",testType="hy
perG",pvalueT=0.1,FDR.correction=TRUE,geneExpressionProfile=NULL) 
w<-
geneAnswersBuilder(DOWNsENTREZ,"org.Hs.eg.db",categoryType="KEGG",testType="hyp
erG",pvalueT=0.1,FDR.correction=TRUE,geneExpressionProfile=NULL) 
 
 
  xx<-geneAnswersReadable(x) 
  yy<-geneAnswersReadable(y) 
  zz<-geneAnswersReadable(z) 
  ww<-geneAnswersReadable(w) 
 
 
  
  #if chartType in "chartPlotter" is given as "all", it opens 
  #two devices and this raises problems in drawing. this loop 
  #is written for this problem... 
 
  TYPE_CHART<-c("pieChart","barPlot") 
 
  for (m in 1:length(TYPE_CHART)){ 
 
   if(length(rownames(xx@enrichmentInfo))>1){ 
 
   pdf(file=paste(colnames(results)[i], 
"_UPREG_GO.BP_TOP5_",TYPE_CHART[m],".pdf",sep=""),width=14,height=9) 
   ChartPlotter(xx, chartType=TYPE_CHART[m]) 
   dev.off() 
   } 
   else{print(paste("The only term: ",xx@enrichmentInfo, 
sep="\n"))} 
 
   if(length(rownames(yy@enrichmentInfo))>1){ 
   pdf(file=paste(colnames(results)[i], 
"_UPREG_KEGG_TOP5_",TYPE_CHART[m],".pdf",sep=""),width=14,height=9) 
   ChartPlotter(yy, chartType=TYPE_CHART[m]) 
   dev.off() 
   } 
 
   else{print(paste("The only term: ",yy@enrichmentInfo, 
sep="\n"))} 
 
 
   if(length(rownames(zz@enrichmentInfo))>1){ 
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   pdf(file=paste(colnames(results)[i], 
"_DOWNREG_GO.BP_TOP5_",TYPE_CHART[m],".pdf",sep=""),width=14,height=9) 
   ChartPlotter(zz, chartType=TYPE_CHART[m]) 
   dev.off() 
   } 
   else{print(paste("The only term: ",zz@enrichmentInfo, 
sep="\n"))} 
 
   if(length(rownames(ww@enrichmentInfo))>1){ 
   pdf(file=paste(colnames(results)[i], 
"_DOWNREG_KEGG_TOP5_",TYPE_CHART[m],".pdf",sep=""),width=14,height=9) 
   ChartPlotter(ww, chartType=TYPE_CHART[m]) 
   dev.off() 
   } 
   else{print(paste("The only term: ",ww@enrichmentInfo, 
sep="\n"))} 
  } 
   
 } 
  
 
AllEntrez<-unlist(as.list(EntrezIDMaP[AllSignifProbes])) 
AllEntrez<-AllEntrez[!is.na(AllEntrez)] 
 
xAll<-
geneAnswersBuilder(AllEntrez,"org.Hs.eg.db",categoryType="GO.BP",testType="hype
rG", pvalueT=0.1, FDR.correction=TRUE,geneExpressionProfile=NULL) 
yAll<-
geneAnswersBuilder(AllEntrez,"org.Hs.eg.db",categoryType="KEGG",testType="hyper
G", pvalueT=0.1, FDR.correction=TRUE,geneExpressionProfile=NULL) 
xxAll<-geneAnswersReadable(xAll) 
yyAll<-geneAnswersReadable(yAll) 
 
for (m in 1:length(TYPE_CHART)){ 
pdf(file=paste("AllSignifProbes_GO.BP_TOP5",TYPE_CHART[m],".pdf",sep=""),width=
14,height=9) 
ChartPlotter(xxAll, chartType=TYPE_CHART[m]) 
dev.off() 
print("Graph for KEGG") 
pdf(file=paste("AllSignifProbes_KEGG_TOP5",TYPE_CHART[m],".pdf",sep=""),width=1
4,height=9) 
ChartPlotter(yyAll, chartType=TYPE_CHART[m]) 
dev.off() 
} 
} 
#End of the Function..... 
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ChartPlotter FUNCTION 
 
ChartPlotter<-function (x, chartType = c("pieChart", "barPlot", "all"), sortBy 
= c("geneNum","pvalue", "foldChange", "oddsRatio", "correctedPvalue"), 
newWindow = FALSE, ...){ 
    chartType <- match.arg(chartType) 
    sortBy <- match.arg(sortBy) 
    if ((sortBy == "correctedPvalue") & !("fdr p value" %in%  
        colnames(x@enrichmentInfo)))  
        stop("input GeneAnswer instance does not contain corrected p value!!!") 
    orderby <- switch(sortBy, geneNum = c("genes in Category",  
        "TRUE"), pvalue = c("p value", "FALSE"), foldChange = c("fold of 
overrepresents",  
        "TRUE"), oddsRatio = c("odds ratio", "FALSE"), correctedPvalue = c("fdr 
p value",  
        "FALSE")) 
    y <- x 
    y@enrichmentInfo <- x@enrichmentInfo[order(x@enrichmentInfo[,  
        orderby[1]], decreasing = as.logical(orderby[2])), ] 
    y@genesInCategory <- x@genesInCategory[rownames(y@enrichmentInfo)] 
    PlotCharts(y@enrichmentInfo, chartType = chartType, specifiedCols = 
orderby[1],  
        ylab = orderby[1], newWindow = FALSE, ...) 
} 
#End of the Function..... 
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PlotCharts FUNCTION 
PlotCharts<-function (x, chartType = c("pieChart", "barPlot", "all"), 
specifiedCols = c("genes in Category"),  
    top = 5, newWindow = FALSE, ...)  
{ 
    chartType <- match.arg(chartType) 
    if (is.matrix(x) | is.data.frame(x)) { 
        if (all(specifiedCols %in% colnames(x)) & (length(specifiedCols) ==  
            1)) { 
            if ((chartType == "pieChart") | (chartType == "all")) { 
                if (newWindow)  
                  x11() 
                pie(as.numeric(x[1:top, specifiedCols[1]]), labels = 
rownames(x)[1:top],  
                  col = rainbow(top), radius = 0.9, main = paste("Top ",  
                    top, " Categories Distribution based on ",  
                    specifiedCols, sep = ""), ...) 
            } 
            if ((chartType == "barPlot") | (chartType == "all")) { 
                if (newWindow | chartType == "all")  
                  x11() 
                barplot(as.numeric(x[1:top, specifiedCols[1]]),  
                  names.arg = rownames(x)[1:top], space = 0.6,  
                  col = rainbow(5), main = paste("Top ", top,  
                    " Categories Distribution based on ", specifiedCols,  
                    sep = ""), ...) 
            } 
        } 
        else { 
            stop("One or two given names are not column names in the original 
matrix!") 
        } 
    } 
    else { 
        stop("The input data format is not a matrix or dataframe!") 
    } 
} 
#End of the function..... 
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KG_HyperG FUNCTION 
KG_HyperG<- function(GeneList, universe_GeneIds, annotation, categoryName, 
pValcutoff, testDir){ 
 
#GeneList: list of the genes to be tested. probe ids required. 
#annotation: A string giving the name of the annotation data 
#   package for the chip used to generate the data. 
#   e.g. 'hgu133plus2' 
#categoryName: string giving the name of the category for testing. 
#   e.g. "KEGG", "PFAM" 
#pValcutoff: p-value to be used for significance treshold. 
#   default is 0.05 
#testDir: direction of the test, "over" for overrepresentation and 
#  "under" for underrepresentation. 
 
annotation<-
match.arg(annotation,c("hgu133plus2.db","hgu133a.db","hgu133b.db","hgu95a.db","
hgu95b.db")) 
categoryName<-match.arg(categoryName,c("KEGG","PFAM")) 
testDir<-match.arg(testDir,c("over","under")) 
 
if(is.vector(universe_GeneIds)){ 
universe_GeneIds<-universe_GeneIds 
} 
else{ 
return<-universe_GeneIds 
} 
 
assign("annotation", annotation) 
 
require(annotation,character.only=TRUE) 
require(KEGG.db) 
 
switch (annotation, 
hgu133plus2.db= assign("GeneList", hgu133plus2ENTREZID[GeneList]), 
hgu133a.db= assign("GeneList", hgu133aENTREZID[GeneList]), 
hgu133b.db= assign("GeneList", hgu133bENTREZID[GeneList]), 
hgu95a.db= assign("GeneList", hgu95aENTREZID[GeneList]), 
hgu95b.db= assign("GeneList", hgu95bENTREZID[GeneList]) 
) 
 
 
GeneList<-as.vector(unlist(as.list(GeneList))) 
GeneList<-GeneList[!is.na(GeneList)] 
GeneList<-GeneList[!duplicated(GeneList)] 
 
 
HypObj<-
new("KEGGHyperGParams",geneIds=GeneList,universeGeneIds=universe_GeneIds, 
annotation=annotation,categoryName=categoryName,pvalueCutoff=pValcutoff,testDir
ection=testDir) 
TestResult<-hyperGTest(HypObj) 
 
results<-as.data.frame(TestResult@pvalues) 
 
SignifKEGGs_ID<-rownames(results)[which(results<=pValcutoff)] 
assign("SignifKEGGIDs", SignifKEGGs_ID, envir=.GlobalEnv) 
 
rownames(results)<-KEGGPATHID2NAME[rownames(results)] 
 
SignifKEGGsNAMES<-rownames(results)[which(results<=pValcutoff)] 
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ExpTitle<-paste("KEGG Pathways overrepresented in your data 
:","*********************","*********************", sep="\n") 
write(ExpTitle, file="KEGG_HyperGeometricTest_Results.txt") 
write(SignifKEGGsNAMES, file="KEGG_HyperGeometricTest_Results.txt", 
append=TRUE) 
 
 
} 
#End of the function...
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GO_HyperG FUNCTION 
 
GO_HyperG<- function(ontology, conditional, GeneList, universe_GeneIds, 
annotation, categorySubsetIds, pValcutoff, testDir){ 
 
 
 
#ontology:  A string specifying the GO ontology to use. Must be 
#   one of "BP", "CC", or "MF". 
#conditional: A logical indicating whether the calculation should 
#   condition on the GO structure.'TRUE' or 'FALSE' 
#GeneList:  list of the genes to be tested. probe ids required. 
#universeGeneIds: Object of class "ANY": A vector of gene ids in the 
#   same format as geneIds defining a subset of the gene 
#   ids on the chip that will be used as the universe for 
#   the hypergeometric calculation. 
#   If this is NULL or has length zero, then all gene ids 
#   on the chip will be used. 
#annotation: A string giving the name of the annotation data 
#   package for the chip used to generate the data. 
#    e.g. "hgu133plus2.db" 
#categorySubsetIds: Object of class "ANY": If the test method 
#    supports it, can be used to specify a subset of 
#    category ids to include in the test instead of 
#    all possible category ids. 
#pValcutoff: p-value to be used for significance treshold. 
#   default is 0.05 
#testDir:  direction of the test, "over" for overrepresentation 
#   and "under" for underrepresentation. 
 
 
library(Category) 
library(GOstats) 
 
annotation<-
match.arg(annotation,c("hgu133plus2.db","hgu133a.db","hgu133b.db","hgu95a.db","
hgu95av.db","hgu95b.db")) 
categoryName<-c("GO") 
datPkg<-DatPkgFactory(annotation) 
testDir<-match.arg(testDir,c("over","under")) 
ontology<-match.arg(ontology,c("BP", "CC", "MF")) 
 
 
if(is.vector(universe_GeneIds)){ 
universe_GeneIds<-universe_GeneIds 
} 
else{ 
return<-universe_GeneIds 
} 
 
 
assign("annotation", annotation) 
 
require(annotation,character.only=TRUE) 
 
 
switch (annotation, 
hgu133plus2.db= assign("GeneList", hgu133plus2ENTREZID[GeneList]), 
hgu133a.db= assign("GeneList", hgu133aENTREZID[GeneList]), 
hgu133b.db= assign("GeneList", hgu133bENTREZID[GeneList]), 
hgu95a.db= assign("GeneList", hgu95aENTREZID[GeneList]), 
hgu95b.db= assign("GeneList", hgu95bENTREZID[GeneList]) 
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) 
 
 
GeneList<-as.vector(unlist(as.list(GeneList))) 
GeneList<-GeneList[!is.na(GeneList)] 
GeneList<-GeneList[!duplicated(GeneList)] 
 
 
HypObj<-new("GOHyperGParams",ontology=ontology, conditional=conditional, 
geneIds=GeneList,universeGeneIds=universe_GeneIds, 
annotation=annotation,categorySubsetIds=categorySubsetIds,categoryName=category
Name,datPkg=datPkg, pvalueCutoff=pValcutoff,testDirection=testDir) 
TestResult<-hyperGTest(HypObj) 
 
summGO<-summary(TestResult) 
write.table(summGO, file="GO_hyperGTest_Results.xls", sep="\t") 
 
} 
#End of the function...
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Grapher FUNCTION 
 
Grapher<-function(ndata, foldchangeData, SignifKEGGIDs){ 
 
library(RColorBrewer) 
library(org.Hs.eg.db) 
library(RBGL) 
library(grid) 
library(KEGG.db) 
library(KEGGgraph) 
 
EntrezIDMaP <- hgu133plus2ENTREZID 
TempNamesfc<-unlist(as.list(EntrezIDMaP[rownames(fc)])) 
rownames(fc)<-TempNamesfc 
fc<-as.data.frame(fc) 
fc<-fc[which(!is.na(rownames(fc))),] 
 
deKID <- translateGeneID2KEGGID(rownames(fc)) 
 
 
TempNamesndata<-unlist(as.list(EntrezIDMaP[rownames(ndata)])) 
Tempndata<-ndata 
rownames(Tempndata)<-TempNamesndata 
ndata_framed<-as.data.frame(Tempndata) 
ndata_framed<-ndata_framed[which(!is.na(rownames(ndata_framed))),] 
 
allKID <- translateGeneID2KEGGID(rownames(ndata_framed)) 
 
 
FileList<-list() 
for (i in 1:length(SignifKEGGIDs)){ 
FileList[i]<-
system.file(paste("extdata/hsa",SignifKEGGIDs[i],".xml",sep=""),package="KEGGgr
aph") 
} 
FileList<-FileList[is.na(charmatch(FileList,""))] 
FileList<-unlist(FileList) 
 
 
 
for (i in 1:length(FileList)){ 
 gg<-parseKGML(FileList[i]) 
 g<-KEGGpathway2Graph(gg,expandGenes=TRUE) 
 gGeneID<-translateKEGGID2GeneID(nodes(g)) 
 gSymbol<-sapply(gGeneID, function(x) mget(x, org.Hs.egSYMBOL, 
ifnotfound=NA)[[1]]) 
 
 for(j in 1:ncol(fc)){ 
  ar <- 20 
  cols <- rev(colorRampPalette(brewer.pal(6, "RdBu"))(ar))  
  logfcs<-fc[,j][match(nodes(g),deKID)] 
  names(logfcs) <- nodes(g) 
  logfcs[is.na(logfcs)] <- 0 
  if(min(logfc)<=0){ 
  incol <- round((logfcs+(-min(logfcs)+1))*5) 
  } 
  else{ 
  incol<- round((logfcs)*5) 
  } 
  incol[incol>ar] <- ar 
  undetected <- !nodes(g) %in% allKID 
  logcol <- cols[incol] 
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  logcol[logfcs==0] <- "darkgrey" 
  logcol[undetected] <- "yellow" 
  names(logcol) <- names(logfcs) 
  nA <- makeNodeAttrs(g, fillcolor=logcol, label=gSymbol, width=10, 
height=1.2) 
  par(mar=c(3,5,0,5), mgp=c(0,0,0)) 
  layout(mat=matrix(c(rep(1,8),2), ncol=1, byrow=TRUE)) 
#jpeg(file=paste(colnames(fc)[j],gg@pathwayInfo@title, ".jpeg", sep="_")) 
  plot(g, "dot", nodeAttrs=nA, 
main=paste(colnames(fc)[j],gg@pathwayInfo@title, sep=" ")) 
  image(as.matrix(seq(1,ar)), col=cols, yaxt="n", xaxt="n") 
  mtext("down-regulation", side=1,  at=0, line=1) 
  mtext("up-regulation", side=1,  at=1, line=1) 
#dev.off() 
 
 } 
 
} 
} 
#end of the function... 
